<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0907245513
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2006
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SETRAL 100MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SERTRALINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1055]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Dallah Health Care Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SETRAL contains the active substance Sertraline. Sertraline is one of a group of medicines called Selective Serotonin Re-uptake Inhibitors (SSRIs); these medicines are used to treat depression and/or anxiety disorders. SETRAL can be used to treat: □ Depression and prevention of recurrence of depression (in adults) □ Social anxiety disorder (in adults) □ Post traumatic stress disorder (PTSD) (in adults) □ Panic disorder (in adults) □ Obsessive compulsive disorder (OCD) (in adults and children and adolescents aged 6-17 years old). - Depression is a clinical illness with symptoms like feeling sad, unable to sleep properly or to enjoy life as you used to. - OCD and Panic disorders are illnesses linked to anxiety with symptoms like being constantly troubled by persistent ideas (obsessions) that make you carry out repetitive rituals (compulsions). - PTSD is a condition that can occur after a very emotionally traumatic experience, and has some symptoms that are similar to depression and anxiety. Social anxiety disorder (social phobia) is an illness linked to anxiety. It is characterised by feelings of intense anxiety or distress in social situations (for example: talking to strangers, speaking in front of groups of people, eating or drinking in front of others or worrying that you might behave in an embarrassing manner). Your doctor has decided that this medicine is suitable for treating your illness. You should ask your doctor if you are unsure why you have been given SETRAL.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take SETRAL: □ If you are allergic to Sertraline or any of the other ingredients of SETRAL (listed in section 6). □ If you are taking or have taken medicines called monoamine oxidase inhibitors (MAOIs such as selegiline, moclobemide) or MAOI like drugs (such as linezolid). If you stop treatment with Sertraline, you must wait until at least one week before you start treatment with a MAOI. After stopping treatment with a MAOI, you must wait at least 2 weeks before you can start treatment with Sertraline. □ If you are taking another medicine called Pimozide (a medicine for mental disorders such as psychosis). Take special care with SETRAL: Talk to your doctor or pharmacist before taking SETRAL. Medicines are not always suitable for everyone. Tell your doctor before you take SETRAL, if you suffer from or have suffered in the past from any of the following conditions: □ If you have epilepsy (fit) or a history of seizures. If you have a fit (seizure), contact your doctor immediately. □ If you have suffered from manic depressive illness (bipolar disorder) or schizophrenia. If you have a manic episode, contact your doctor immediately. □ If you have or have previously had thoughts of harming or killing yourself (see below-Thoughts of suicide and worsening of your depression or anxiety disorder). □ If you have Serotonin Syndrome. In rare cases this syndrome may occur when you are taking certain medicines at the same time as Sertraline. (For symptoms, see section 4. Possible Side Effects). Your doctor will have told you whether you have suffered from this in the past. □ If you have low sodium level in your blood, since this can occur as a result of treatment with SETRAL. You should also tell your doctor if you are taking certain medicines for hypertension, since these medicines may also alter the sodium level in your blood. □ If you are elderly as you may be more at risk of having low sodium level in your blood (see above). □ If you have Liver disease; your doctor may decide that you should have a lower dose of SETRAL. □ If you have Diabetes; your blood glucose levels may be altered due to SETRAL and your diabetes medicines may need to be adjusted. □ If you have suffered from bleeding disorders or have been taking medicines which thin the blood (e.g. acetylsalicyclic acid (aspirin), or warfarin) or may increase the risk of bleeding. □ If you are a child or adolescent under 18 years old. SETRAL should only be used to treat children and adolescents aged 6-17 years old, suffering from obsessive compulsive disorder (OCD). If you are being treated for this disorder, your doctor will want to monitor you closely (see below Use in children and adolescents). □ If you are having electro-convulsive therapy (ECT). □ If you have eye problems, such as certain kinds of glaucoma (increased pressure in the eye). □ If you have been told that you have an abnormality of your heart tracing after an electrocardiogram (ECG) known as prolonged QT interval. □ If you have heart disease, low potassium levels or low magnesium levels, family history of QT prolongation, low heart rate and concomitant use of medications which prolong QT interval. Restlessness/Akathisia: The use of Sertraline has been linked to a distressing restlessness and need to move, often being unable to sit or stand still (akathisia). This is most likely to occur during the first few weeks of treatment. Increasing the dose may be harmful so if you develop such symptoms you should talk to your doctor. Withdrawal reactions: Side effects relating to stopping treatment (withdrawal reactions) are common, particularly if the treatment is stopped suddenly (see section 3 If you stop taking SETRAL and section 4 Possible side effects). The risk of withdrawal symptoms depends on the length of treatment, dosage and the rate at which the dose is reduced. Generally, such symptoms are mild to moderate. However, they can be serious in some patients. They normally occur within the first few days after stopping treatment. In general, such symptoms disappear on their own and wear off within 2 weeks. In some patients they may last longer (2-3 months or more). When stopping treatment with Sertraline it is recommended to reduce the dose gradually over a period of several weeks or months and you should always discuss the best way of stopping treatment with your doctor. Thoughts of suicide and worsening of your depression or anxiety disorder: If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer. You may be more likely to think like this: □ If you have previously had thoughts about killing or harming yourself. □ If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant. If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away. You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour. Sexual problems: Medicines like SETRAL (so called SSRIs) may cause symptoms of sexual dysfunction (see section 4). In some cases, these symptoms have continued after stopping treatment. Children and adolescents: Sertraline should not usually be used in children and adolescents less than 18 years old, except for patients with Obsessive Compulsive Disorder (OCD). Patients under 18 have an increased risk of undesirable effects, such as suicide attempt, thoughts of harming or killing themselves (suicidal thoughts) and hostility (mainly aggressiveness, oppositional behaviour and anger) when they are treated with this class of medicines. Nevertheless, it is possible that your doctor decides to prescribe SETRAL to a patient under 18 if it is in the patient&#39;s interest. If your doctor has prescribed SETRAL to you and you are less than 18 years old and you want to discuss this, please contact him/her. Furthermore, if any of the symptoms listed above appear or worsen while you are taking SETRAL, you should inform your doctor. Also, the long-term safety of SETRAL in regard to growth, maturation and learning (cognitive) and behavioural development in this age group has not yet been demonstrated.- SSRIs/SNRIs may increase the risk of postpartum hemorrhage. Taking other medicines with SETRAL: Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. Some medicines can affect the way SETRAL works, or SETRAL itself can reduce the effectiveness of other medicines taken at the same time. Taking SETRAL together with the following medicines may cause serious side effects: □ Medicines called monoamine oxidase inhibitors (MAOIs), like moclobemide (to treat depression) and selegiline (to treat Parkinson&rsquo;s disease), the antibiotic linezolid and methylene blue (to treat high levels of methaemoglobin in the blood). Do not use SETRAL together with these medicines. □ Medicines to treat mental disorders such as psychosis (pimozide). Do not use SETRAL together with pimozide. Talk to your doctor if you are taking the following medicine: □ Medicines containing amphetamines (used to treat attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity). □ Herbal medicine containing St. John&rsquo;s Wort (Hypericum perforatum). The effects of St. John&rsquo;s Wort may last for 1-2 weeks □ Products containing the amino acid tryptophan □ Medicines to treat severe pain (e.g. tramadol) □ Medicines used in anaesthesia or to treat chronic pain (eg.fentanyl, mivacurium and suxamethonium) □ Medicines to treat migraines (e.g. sumatriptan) □ Blood thinning medicine (warfarin) □ Medicines to treat pain/arthritis (Non steroidal anti-inflammatory drug (NSAID) such as ibuprofen, acetylsalicylic acid (aspirin)) □ Sedatives (diazepam) □ Diuretics (also called &lsquo;water&rsquo; tablets) □ Medicines to treat epilepsy (phenytoin, phenobarbital, carbamazepine) □ Medicines to treat diabetes (tolbutamide) □ Medicines to treat excessive stomach acid, ulcers and heartburn (cimetidine,omeprazole, lanzoprazole, pantoprazole, rabeprazole) □ Medicines to treat mania and depression (lithium) □ Other medicines to treat depression (such as amitriptyline, nortriptyline, nefazodone, fluoxetine, fluvoxamine) □ Medicines to treat schizophrenia and other mental disorders (such as perphenazine, levomepromazine and olanzapine) □ Medicines used to treat high blood pressure, chest pain or regulate the rate and rhythm of the heart (such as verapamil, diltiazem,flecainide, propafenone) □ Medicines used to treat bacterial infections (such as rifampicin, clarithromycin, telithromycin, erythromycin) □ Medicines used to treat fungal infections (such as ketoconazole, itraconazole, posaconazole, voriconazole, fluconazole) □ Medicines used to treat HIV/AIDS and Hepatitis C (protease inhibitors such as ritonavir, telaprevir) □ Medicines used to prevent nausea and vomiting after an operation or chemotherapy (aprepitant) □ Medicines known to increase the risk of changes in the electrical activity of the heart (e.g. some antipsychotics and antibiotics). Taking SETRAL with food, drink and alcohol: □ SETRAL tablets can be taken with or without food □ Alcohol should be avoided whilst taking SETRAL □ Sertraline should not be taken in combination with grapefruit juice, as this may increase the level of Sertraline in your body. Pregnancy, breastfeeding and fertility: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. The safety of Sertraline has not been fully established in pregnant women. Sertraline will only be given to you when pregnant if your doctor considers that the benefit for you is greater than any possible risk to the developing baby. If you take SETRAL near the end of your pregnancy there may be an increased risk of heavy vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders. Your doctor or midwife should be aware that you are taking SETRAL so they can advise you. When taken during pregnancy, particularly in the last 3 months of pregnancy, medicines like SETRAL may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately. Your newborn baby might also have other conditions, which usually begin during the first 24 hours after birth. Symptoms include: □ Trouble with breathing □ A blueish skin or being too hot or cold □ Blue lips □ Vomiting or not feeding properly □ Being very tired, not able to sleep or crying a lot □ Stiff or floppy muscles □ Tremors, jitters or fits □ Increased reflex reactions □ Irritability, □ Low blood sugar If your baby has any of these symptoms when it is born, or you are concerned about your baby&rsquo;s health, contact your doctor or midwife who will be able to advise you. There is evidence that Sertraline passes into human breast milk. Sertraline should only be used in women during breast-feeding, if your doctor considers that the benefit exceeds any possible risk to the baby. Some medicines like sertraline may reduce the quality of sperm in animal studies. Theoretically, this could affect fertility, but impact on human fertility has not been observed as yet. Observational data indicate an increases risk (less than 2- fold) of post partum hemorrhage following SSRI/ SNRI exposure within the month prior to birth. Driving and using machines: Psychotropic drugs such as Sertraline may influence your ability to drive or use machines. You should therefore not drive or operate machinery, until you know how this medication affects your ability to perform these activities.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take SETRAL exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is: Adults: □ Depression and Obssessive Compulsive Disorder: For depression and OCD, the usual effective dose is 50 mg/day. The daily dose may be increased in 50 mg increments and at intervals of at least one week over a period of weeks. The maximum recommended dose is 200 mg/day. □ Panic disorder, Social anxiety disorder and Post Traumatic Stress Disorder: For panic disorder, social anxiety disorder and post traumatic stress disorder, treatment should be started at 25 mg/day, and increased to 50 mg/day after one week. The daily dose then may be increased in 50 mg increments over a period of weeks. The maximum recommended dose is 200 mg/day. Use in children and adolescents: SETRAL must only be used to treat children and adolescents suffering from OCD (Obsessive Compulsive Disorder) aged 6-17 years old. Obsessive Compulsive Disorder: □ Children aged 6 to 12: the recommended starting dose is 25 mg daily. After one week, your doctor may increase this to 50 mg daily. The maximum dose is 200 mg daily. □ Adolescents aged 13 to 17: the recommended starting dose is 50 mg daily. The maximum dose is 200 mg daily. If you have liver or kidney problems, please tell your doctor and follow the doctor&rsquo;s instructions. Method of administration: □ SETRAL tablets may be taken with or without food. □ Take your medication once daily either in the morning or evening. Your doctor will advise you on how long to take this medication. This will depend on the nature of your illness and how well you are responding to the treatment. It may take several weeks before your symptoms begin to improve. Treatment of depression should usually continue for 6 months after improvement. If you take more SETRAL than you should: If you accidentally take too much SETRAL contact your doctor at once or go to the nearest hospital casualty department. Always take the labelled medicine package with you, whether there is any medication left or not. Symptoms of overdose may include drowsiness, nausea and vomiting, rapid heart rate, shaking, agitation, dizziness and in rare cases unconsciousness. If you forget to take SETRAL: Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, do not take the missed dose. Just take the next dose at the right time. If you stop taking SETRAL: Do not stop taking SETRAL unless your doctor tells you to. Your doctor will want to gradually reduce your dose of SETRAL over several weeks, before you finally stop taking this medicine. If you suddenly stop taking this medicine you may experience side effects such as dizziness, numbness, sleep disturbances, agitation or anxiety, headaches, feeling sick, being sick and shaking. If you experience any of these side effects, or any other side effects whilst stopping taking SETRAL, please speak to your doctor. If you have any questions on the use of this product, ask your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, SETRAL can cause side effects, although not everybody gets them. Nausea is the most common side effect. The side effects depend on the dose and often disappear or lessen with continued treatment. Tell your doctor immediately: If you experience any of the following symptoms after taking this medicine, these symptoms can be serious. □ If you develop a severe skin rash that causes blistering (erythema multiforme), (this can affect the mouth and tongue). These may be signs of a condition known as Stevens Johnson Syndrome, or Toxic Epidermal Necrolysis (TEN). Your doctor will stop your treatment in these cases. □ Allergic reaction or allergy, which may include symptoms such as an itchy skin rash, breathing problems, wheezing, swollen eyelids, face or lips. □ If you experience agitation, confusion, diarrhoea, high temperature and blood pressure, excessive sweating and rapid heartbeat. These are symptoms of Serotonin Syndrome. In rare cases this syndrome may occur when you are taking certain medicines at the same time as Sertraline. Your doctor may wish to stop your treatment. □ If you develop yellow skin and eyes which may mean liver damage. □ If you experience depressive symptoms with ideas of harming or killing yourself (suicidal thoughts). □ If you start to get feelings of restlessness and are not able to sit or stand still after you start to take SETRAL. You should tell your doctor if you start to feel restless. □ If you have a fit (seizure). □ If you have a manic episode (see section 2 &ldquo;Take special care with SETRAL&rdquo;). The following side effects were seen in clinical trials in adults and after marketing. Very common (may affect more than 1 in 10 people): Insomnia, dizziness, sleepiness, headache, diarrhoea, feeling sick, dry mouth, ejaculation failure, fatigue. Common (may affect up to 1 in 10 people): □ Chest cold, sore throat, runny nose □ Decreased appetite, increased appetite □ Anxiety, depression, agitation, decreased sexual interest, nervousness, feeling strange, nightmare, teeth grinding □ Shaking, muscular movement problems (such as moving a lot, tense muscles, difficulty walking and stiffness, spasms and involuntary movements of muscles)*, numbness and tingling, muscle tense, lack of attention, abnormal taste □ Visual disturbance □ Ringing in ears □ Palpitations □ Hot flush □ Yawning □ Upset stomach, constipation, abdominal pain, vomiting, gas □ Increased sweating, rash □ Back pain, joint pain, muscle pain □ Menstrual irregularities, erectile dysfunction □ Malaise, chest pain, weakness, fever □ Weight increased □ Injury Uncommon (may affect up to 1 in 100 people): □ Gastroenteritis, ear infection □ Tumour □ Hypersensitivity, seasonal allergy □ Low thyroid hormones □ Suicidal thoughts, suicidal behaviour*, psychotic disorder, thinking abnormal, lack of caring, hallucination, aggression, euphoric mood, paranoia □ Amnesia, decreased feeling, involuntar y muscle contractions, passing out, moving a lot, migraine, convulsion, dizziness while standing up, abnormal coordination, speech disorder □ Enlarged pupils □ Ear pain □ Fast heartbeat, heart problem □ Bleeding problems (such as stomach bleeding)*, high blood pressure, flushing, blood in urine □ Shortness of breath, nose bleed, breathing difficulty, possible wheezing □ Tarry stools, tooth disorder, inflammation of the oesophagus, tongue problem, haemorrhoids, increased saliva, difficulty swallowing, burping, tongue disorder □ Eye swelling, hives, hair loss, itching, purple spots on skin, skin problem with blisters, dry skin, face oedema, cold sweat, □ Osteoarthritis, muscle twitching, muscle cramps*, muscular weakness □ Increase in frequency of urination, problem urinating unable to urinate, urinary incontinence, increase in urination, nighttime urination □ Sexual dysfunction, excessive vaginal bleeding, vaginal haemorrhage, female sexual dysfunction □ Swelling in legs, chills, difficulty walking, thirst □ Increase in liver enzyme levels, weight decreased □ Cases of suicidal ideation and suicidal behaviours have been reported during sertraline therapy or early after treatment discontinuation (see section 2). Rare (may affect up to 1 in 1000 people): □ Diverticulitis, swollen lymph glands, decrease in clotting cells*, decrease in white blood cells* □ Severe allergic reaction □ Endocrine problems* □ High cholesterol, problems controlling blood sugar levels (diabetes), low blood sugar, increase in blood sugar levels*, low blood salt* □ Physical symptoms due to stress or emotions, terrifying abnormal dreams*, drug dependence, sleep walking, premature ejaculation □ Coma, abnormal movements, difficulty moving, increased sensation, sudden severe headache (which may be a sign of a serious condition known as reversible cerebral vasoconstriction syndrome (RCVS))*, sensory disturbance □ Spots in front of eyes, glaucoma, double vision, light hurts eye, blood in the eye, unequal sized pupils*, vision abnormal*, tear problem □ Heart attack, light-headedness, fainting, or chest discomfort which could be signs of changes in the electrical activity (seen on electrocardiogram) or abnormal rhythm of the heart*, slow heartbeat □ Poor circulation of arms and legs □ Breathing fast, progressive scarring of lung tissue (interstitial lung disease)*, closing up of throat, difficulty talking, breathing slow, hiccups □ Mouth ulceration, pancreatitis*, blood in stool, tongue ulceration, sore mouth □ Problems with liver function, serious liver function problems*, yellow skin and eyes (jaundice)* □ Skin reaction to sun*, skin oedema*, hair texture abnormal, skin odour abnormal, hair rash □ Breakdown of muscle tissue*, bone disorder □ Urinary hesitation, decreased urination □ Breast discharge, dry vaginal area, genital discharge, red painful penis and foreskin, breast enlargement*, prolonged erection □ hernia, drug tolerance decreased □ Increase in blood cholesterol levels, abnormal laboratory tests*, semen abnormal, problems with clotting* □ Relaxation of blood vessels procedure. Not known: frequency cannot be estimated from the available data: □ Lockjaw* □ Bedwetting* □ Partial loss of vision □ Inflammation of the colon (causing diarrhea) □ Heavy vaginal bleeding shortly after birth (postpartum haemorrhage), see Pregnancy, breast-feeding and fertility in section 2 for more information* * Side effect reported after marketing. Additional side effects in children and adolescents: In clinical trials with children and adolescents, the side effects were generally similar to adults (see above). The most common side effects in children and adolescents were headache, insomnia, diarrhoea and feeling sick. Symptoms that can occur when treatment is discontinued: If you suddenly stop taking this medicine you may experience side effects such as dizziness, numbness, sleep disturbances, agitation or anxiety, headaches, feeling sick, being sick and shaking (see section 3. &ldquo;If you stop taking SETRAL&rdquo;). An increased risk of bone fractures has been observed in patients taking this type of medicines</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ Keep out of the reach and sight of children □ Do not store above 30 &deg;C □ Do not use SETRAL after the expiry date which is stated on the carton and on the blister, after (EXP).Date. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>□ The active substance is Sertraline. Each SETRAL 50 and 100 Film Coated Tablet contains Sertraline 50 and 100 mg, respectively, as Sertraline Hydrochloride. □ The other ingredients are: microcrystalline cellulose 50 micrometer, anhydrous calcium hydrogen phosphate, sodium starch glycolate type A, hydroxypropyl cellulose, magnesium stearate, hydroxypropyl methylcellulose 2910, polyethylene glycol 400, titanium dioxide, white beeswax</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                □ SETRAL 50 Tablets are white to off-white, circular 
shallow biconvex film coated tablet debossed with 
“SL50” on one side and plain on the other side. 
□ SETRAL 100 Tablets are white to off-white, oval 
biconvex film coated tablet with “SL100” debossed on 
one side and plain on the other side. 
□ Boxes of 10 blistered tablets of SETRAL 50.
□ Boxes of 30 blistered tablets of SETRAL 50.
□ Boxes of 1000 blistered tablets of SETRAL 50.
□ Boxes of 10 blistered tablets of SETRAL 100.
□ Boxes of 1000 blistered tablets of SETRAL 100.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>Saudi Arabia: To report any side effect(s): National Pharmacovigilance Center (NPC): Fax: +966-11-205-7662, SFDA Call center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa</p><p>The Jordanian pharmaceutical manufacturing co.(P.L.C.|)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>یحتوي سیترال على المادة الفعالة سیرترالین. یعتبرسیرترالین واحد من مجموعة الأدویة التي تدعى المثبطات الانتقائیة لاسترداد السیروتونین والتي تستخدم لعلاج الاكتئاب و/أو اضطرابات القلق. یمكن أن یستخدم سیترال لعلاج الحالات التالیة: □ الاكتئاب والوقایة من تكرار حدوث الاكتئاب (لدى البالغین) □ اضطراب القلق الاجتماعي (لدى البالغین) □ اضطراب ما بعد الصدمة (لدى البالغین) □ اضطراب الھلع (لدى البالغین) □ اضطراب الوسواس القھري (لدى البالغین والأطفال والمراھقین الذین تتراوح أعمارھم ما بین ٦ إلى ۱۷ سنة). - الاكتئاب ھو مرض سریري وأعراضھ ھي الشعور بالحزن، عدم القدرة على النوم بشكل صحیح أو الاستمتاع بالحیاة. - الوسواس القھري واضطرابات الھلع ھي حالات مرضیة مرتبطة بالقلق مع أعراض مثل الاضطرب المستمر مع أفكار مستمرة (الھواجس) تجعلك تقوم بشعائر متكررة (أفعال قھریة). - اضطراب ما بعد الصدمة ھي حالة مرضیة تحدث بعد صدمة انفعالیة للغایة، ولدیھا بعض الأعراض المشابھة للاكتئاب والقلق. اضطراب القلق الاجتماعي (الرھاب الاجتماعي) ھو مرض مرتبط بالقلق. ویتمیز بالشعور بالقلق الشدید أو الاضطراب في المواقف الاجتماعیة (مثل، التحدث مع الغرباء، التحدث أمام مجموعة من الأشخاص، تناول الطعام أو الشراب أمام الآخرین أو القلق من أنك قد تتصرف بطریقة محرجة). طبیبك فقط ھو الذي یستطیع أن یقرر إذا كان ھذا الدواء مناسب لمرضك. ً من سبب اعطائك سیترال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استعمال سیترال: □ إذا كنت تعاني من حساسیة لسیرترالین أو لأي من مكونات سیترال الأخرى ( المذكورة في القسم ٦.( □ إذا كنت تتناول أو تناولت الأدویة التي تدعى بمثبطات أكسیداز أحادي الأمین (مثل سیلیجیلین، موكلوبمید) أو الأدویة الشبیھة بمثبطات أكسیداز أحادي الأمین (مثل لینزولید). إذا قمت بإیقاف المعالجة بسیرترالین، فإنھ یجب الانتظار حتى أسبوع واحد على الأقل قبل بدء المعالجة باستخدام مثبطات أكسیداز أحادي الأمین. بعد وقف المعالجة بمثبطات أكسیداز أحادي الأمین فإنھ یجب الانتظار حتى أسبوعین على الأقل قبل البدء بالمعالجة باستخدام سیرترالین. □ إذا كنت تتناول دواء آخر یدعى بیموزاید ( دواء لمعالجة الاضطرابات العقلیة مثل الذھان). الاحتیاطات عند استعمال سیترال: تحدث إلى طبیبك او الصیدلاني قبل تناول سیترال. ً مناسبة لجمیع الأشخاص. أخبر طبیبك قبل الأدویة لا تكون دائما ً من أي من الحالات تناول سیترال إذا كنت تعاني أو عانیت مسبقا التالیة: □ إذا كان لدیك داء الصرع أو تاریخ من النوبات. اتصل بطبیبك على الفور إذا عانیت من نوبة. □ إذا كنت تعاني من اضطراب ھوسي اكتئابي (اضطراب ذو اتجاھین) أو انفصام عقلي. اتصل بطبیبك على الفور إذا كنت تعاني من نوبة ھوسیة. ً أفكار لإیذاء أو قتل نفسك □ إذا كان لدیك أو قد كان لدیك مسبقا (أنظر أدناه، التفكیر في الانتحار وتفاقم حالة الاكتئاب أو القلق). □ إذا كنت تعاني متلازمة السیروتونین، قد تحدث ھذه المتلازمة في حالات نادرة عند تناول أنواع معینة من الأدویة في نفس الوقت الذي تتناول فیھ سیرترالین. (للحصول على الأعراض، أنظر إلى قسم ٤ ،الأعراض الجانبیة). سیخبرك طبیبك ما إذا كنت تعاني من ھذا المرض في الماضي. □ إذا كان مستوى الصودیوم لدیك منخفض في الدم، لأن ذلك ً أن تخبر طبیبك یحدث نتیجة لاستخدام سیترال. یجب علیك أیضا إذا كنت تتناول أنواع معینة من الأدویة لعلاج ارتفاع ضغط الدم، ً من مستوى الصودیوم في الدم. لأن ھذه الأدویة قد تغیرأیضا ً لأنك قد تكون أكثرعرضة لانخفاض مستوى □ إذا كنت مسنا الصودیوم في الدم (أنظر أعلاه). □ إذا كنت تعاني من أمراض الكبد، قد یقرر طبیبك بأنھ یجب أن تتناول جرعة أقل من سیترال. □ إذا كنت تعاني من مرض السكري، قد تتغیر مستویات الجلوكوز في الدم نتیجة استخدام سیترال لذلك قد یكون ھناك حاجة لتعدیل أدویة السكري. □ إذا كنت تعاني من اضطرابات في النزف أوإذا كنت تتناول أدویة ممیعة للدم (مثل، حمض الأسیتیل سالیسیلیك (الأسبیرین)، أو وارفارین) أو أدویة تؤدي زیادة خطر النزف. ً تحت سن ۱۸ سنة. یجب استخدام ً أو مراھقا □ إذا كنت طفلا سیترال فقط للأطفال والمراھقین الذین تتراوح أعمارھم ما بین ٦ إلى ۱۷ سنة والذین یعانون من الوسواس القھري. إذا كنت تتعالج من ھذا الاضطراب فإن طبیبك سیراقبك بشكل دقیق ( أنظر ادناه إلى الأطفال والمراھقین). □ إذا كنت تخضع للمعالجة بالتخلیج الكھربي. □ إذا كنت تعاني من مشاكل في العین، مثل أنواع معینة من الزرق (ارتفاع ضغط العین). □ إذا تم إخبارك بأنك تعاني من عدم انتظام في ضربات القلب بعد إجراء مخطط كھربیة القلب الذي یعرف بطول فترة ال QT. □ إذا كنت تعاني من أمراض في القلب، مستوى البوتاسیوم في الدم قلیل أو مستوى المغنیزیوم في الدم قلیل، لدیك تاریخ عائلي بمشكلة إطالة فترة الQT ،انخفاض معدل ضربات القلب والإستخدام المتزامن مع الأدویة التي تطول فترة ال QT. الأرق/ التململ: یرتبط استخدام سیرترالین بالأرق الضائق ً ما یكون في عدم المقدرة على الجلوس والحاجة إلى التنقل وغالبا ً ما یحدث ھذا خلال أو الوقوف دون حراك (التململ). وغالبا الأسابیع القلیلة الأولى من المعالجة. قد تكون زیادة الجرعة ضارة، لذلك یجب علیك التحدث إلى طبیبك إذا واجھت مثل ھذه الأعراض. الأعراض المتعلقة بوقف المعالجة: الأعراض الجانبیة المتعلقة بوقف المعالجة ھي أعراض شائعة، لا سیما إذا تم إیقاف المعالجة بشكل مفاجئ (أنظر إلى قسم ۳ ،التوقف عن تناول سیترال وقسم ٤ .الأعراض الجانبیة). یعتمد خطر الأعراض المتعلقة بوقف المعالجة على طول مدة العلاج، الجرعة وعلى معدل خفض الجرعة. بشكل عام تكون ھذه الأعراض خفیفة إلى معتدلة، ومع ً ما تحدث ذلك فإنھا قد تكون خطیرة لدى بعض المرضى. وعادة خلال الأیام القلیلة الأولى من وقف العلاج. وبشكل عام فإن مثل ھذه الأعراض تختفي من تلقاء نفسھا في غضون أسبوعین، ولدى بعض المرضى قد تستمر لفترة أطول (۲ إلى ۳ أشھر أو أكثر). عند وقف المعالجة باستخدام سیرترالین فإنھ ینصح بتقلیل الجرعة بشكل تدریجي على مدى فترة عدة أسابیع أو أشھر، ویجب أن تناقش أفضل طریقة لوقف العلاج مع طبیبك. ً التفكیر في الانتحار وتفاقم حالة الاكتئاب أو القلق: إذا كنت مكتئبا و/أو تعاني من القلق فقد یكون لدیك في بعض الأحیان أفكار لإیذاء أو قتل نفسك. ویمكن أن تزداد ھذه الأفكارعند البدء ً بمضادات الاكتئاب لأول مرة، لأن ھذه الأدویة كافة تستغرق وقتا ً ً حوالي أسبوعین ولكنھا تستغرق وقتا ً لكي تعمل، عادة طویلا أطول في بعض الأحیان. قد تكون أكثرعرضة للتفكیر في ھذا القبیل: □ إذا كان لدیك أفكار سابقة لإیذاء أو قتل نفسك. □ إذا كنت من الصغار البالغین. أظھرت التجارب السریریة زیادة خطر السلوك الانتحاري لدى البالغین الذین أعمارھم تقل عن ۲٥ سنة ویعانون من حالات نفسیة وتعالجوا باستخدام مضادت الاكتئاب. إذا كانت لدیك أفكار لإیذاء أو قتل نفسك في أي وقت، فإن علیك الاتصال مباشرة مع طبیبك أو الذھاب إلى المستشفى مباشرة. قد یكون من المفید أن تخبر صدیقك المقرب أو قریب لك بأنك مصاب بحالة اكتئاب أو قلق، واطلب منھم بأن یقرؤا ھذه النشرة وبأن یخبروك في حالة تفاقم حالة الاكتئاب أو القلق لدیك أو إذا كانوا یشعرون بالقلق بشأن التغیرات في سلوكك. المشاكل الجنسیة: قد تسبب أدویة مثل سیترال (أدویة ال SSRIs (أعراض الخلل الوظیفي الجنسي (انظر القسم ٤ .(في بعض الحالات، استمرت ھذه الأعراض بعد التوقف عن العلاج. الأطفال والمراھقین: لا ینبغي استخدام سیرترالین في الأطفال والمراھقین الذین تقل أعمارھم عن ۱۸ سنة، باستثناء المرضى الذین یعانون من حالة الوسواس القھري. المرضى الذین تقل أعمارھم عن ۱۸ سنة لدیھم خطرمتزاید من الأعراض الجانبیة، مثل، محاولة الانتحار، أفكار لإیذاء أو قتل أنفسھم (أفكار انتحاریة) وعداء (بشكل رئیسي عدوانیة وسلوك معارضة وغضب) عندما تتم معالجتھم باستخدام ھذه الفئة من الأدویة. وبالرغم من ذلك فإن من المحتمل بأن یصف الطبیب سیترال للمرضى الذین تقل أعمارھم عن ۱۸ سنة إذا كان ذلك من مصلحة المریض. إذا وصف لك طبیبك سیترال وأنت أقل من ۱۸ سنة ولدیك الرغبة في مناقشة ذلك مع طبیبك یرجى الاتصال بھ. ً على ذلك، إذا ظھرت أو تفاقمت أي من الأعراض علاوة المذكورة أعلاه أثناء تناولك سیترال فإنھ یجب علیك إخبار طبیبك. ولم یتم بعد إثبات مأمونیة سیرترالین طویلة الأمد فیما یتعلق بالنمو والنضج والتعلم والتطور السلوكي على ھذه الفئة العمریة. - قد تزید المثبطات الإنتقائیة لإعادة امتصاص السیروتونین والنورایبینفرین (SNRI/SSRI (خطر حدوث نزیف ما بعد الولادة. تناول سیترال مع أدویة أخرى: ً أو قد إخبر طبیبك أو الصیدلاني إذا كنت تأخذ أو أخذت مؤخرا تتناول أي أدویة أخرى.یمكن لبعض الأدویة أن تؤثر على الطریقة التي یعمل بھا سیترال، أو سیترال نفسھ یمكن أن یقلل من فعالیة الأدویة الأخرى التي اتخذت في نفس الوقت. تناول سیترال مع الأدویة التالیة قد یسبب أعراض جانبیة خطیرة: □ الأدویة التي تسمى مثبطات أوكسیداز أحادي الأمین، مثل، موكلوبیماید (لمعالجة الاكتئاب) و سیلیجیلین (لمعالجة مرض باركنسون) والمضاد الحیوي لینزولید و المثیلین الأزرق (لعلاج ارتفاع مستوى المیثیموغلوبین في الدم). لا تتناول ھذه الأدویة مع سیترال. □ الأدویة التي تستخدم لمعالجة الأضطرابات العقلیة مثل الذھان (بیموزید). لا تتناول سیترال مع بیموزید. أخبر طبیبك إذا كنت تتناول أي من الأدویة التالیة: □ الأدویة التي تحتوي على الأمفیتامینات (المستخدمة لعلاج اضطراب نقص الانتباه وفرط الحركة (ADHD ،(الخدار والسمنة). □ الأدویة العشبیة التي تحتوي على نبتة سانت جون ورت (عشبة ھایبریكوم بیرفوراتوم). قد تستمر تأثیرات نبتة سانت جون ورت لمدة ۱-۲ أسبوع □ المستحضرات التي تحتوي على الحمض الأمیني تریبتوفان □ الأدویة التي تستخدم لمعالجة الألم الشدید (مثل، ترامادول) □ الأدویة التي تستخدم في التخدیر أو لمعالجة الألم المزمن (فینتانیل، میفاكوریوم وسوكسامیثونیوم) □ الأدویة التي تستخدم لمعالجة الصداع النصفي (مثل، سوماتریبتان) □ الأدویة الممیعة للدم (وارفارین) □ الأدویة التي تستخدم لمعالجة الألم/ التھاب المفاصل (الأدویة المضادة للالتھاب غیر الستیرویدیة مثل، الأیبوبروفین، حمض الأسیتیل سالیسیلیك (الأسبیرین)) □ مھدئات (دایازیبام) □ مدرات البول □ الأدویة التي تستخدم لعلاج الصرع (فینیتوین، فینوباربیتال، كاربامازبین) □ الأدویة التي تستخدم لمعلجة السكري (تولبوتاماید) □ الأدویة التي تستخدم لمعالجة حمض المعدة الزائد، القرحات وحرقة المعدة (سیمیتیدین، أومبرازول، لانزوبرازول، بانتوبرازول، رابیبرازول) □ الأدویة التي تستخدم لمعالجة الھوس والاكتئاب (اللیثیوم) □ الأدویة الأخرى التي تستخدم لمعالجة الاكتئاب (مثل، أمیتریبتیلین، نورتریبتیلین، نیفازودون، فلوكسیتین، فلوفوكسامین) □ الأدویة التي تستخدم لمعالجة الانفصام العقلي والاضطرابات العقلیة الأخرى (مثل بیرفینازین و لیفومیبرومازین و أولانزابین) □ الأدویة التي تستخدم لعلاج ارتفاع ضغط الدم، الآم الصدرأو لتنظیم معدل ضربات القلب (مثل فیرابامیل، دیالتیزم، فلیسیانید، بروبافینون) □ الأدویة التي تستخدم لعلاج العدوى البكتیریة (مثل ریفامبیسین، كلاریثرومایسین، تیلثرومایسین، إریثرومایسین) □ الادویة التي تستخدم لعلاج العدوى الفطریة (مثل، كیتوكونازول، ایتراكونازول، بویزاكونازول، فوریكونازول، فلوكونازول) □ الأدویة التي تستخدم لعلاج فیروس نقص المناعة البشریة/الإیدز ولعلاج التھاب الكبد الوبائي نوع ج (مثبطات البروتیاز مثل، ریتونافیر، تیلبریفیر) □ الأدویة التي تستخدم لمنع الغثیان والقيء بعد العملیة أو العلاج الكیمیائي (أبریبیتانت) □ الادویة التي تسبب زیادة خطر التغیراب في النشاط الكھربائي للقلب ( مثل مضادات الذھان و المضادات الحیویة). تناول سیترال مع الطعام، الشراب والكحول: □ یمكن تناول أقراص سیترال مع الطعام أو بدونھ □ ینبغي تجنب الكحول أثناء تناول سیترال □ لا ینبغي تناول عصیر الجریب فروت مع سیرترالین لأن ذلك یؤدي إلى زیادة مستوى السیرترالین في الجسم. الحمل، الرضاعة والخصوبة: ً أو مرضعة أو تعتقدین بأنك حامل أو تخططین إذا كنت حاملا للإنجاب، تحدثي مع طبیبك أو الصیدلي للحصول على المشورة قبل تناول ھذا الدواء. لم تثبت مأمونیة سیرترالین بشكل كامل لدى النساء الحوامل. سیتم إعطاء سیرترالین للنساء الحوامل فقط إذا اعتبر طبیبك بأن الفائدة من تناولھ ھي أكبر من أي خطر محتمل على تطور الجنین. إذا كنتي تأخذین سیترال خلال الفترة القریبة من نھایة الحمل قد یكون ھناك خطر متزاید للإصابة بنزیف مھبلي شدید بعد فترة ِ قصیرة من الولادة، خاصة إذا كان لدیك تاریخ مرضي بالإصابة باضطرابات النزیف. یجب أن یكون طبیبك أو القابلة على درایة بأنك تأخذین سیترال ِ حتى یتمكنا من تقدیم النصیحة لك. عندما تؤخذ أثناء الحمل، وخاصة في الأشھر الثلاثة الأخیرة من الحمل، فإن الأدویة مثل سیترال قد تزید من خطر حدوث حالة خطیرة عند الأطفال، تسمى ارتفاع ضغط الدم الرئوي المستمر عند الولید (PPHN ،(مما یجعل الطفل یتنفس بشكل أسرع ًا. تبدأ ھذه الأعراض عادة خلال الـ۲٤ ساعة الأولى ویبدو مزرق بعد ولادة الطفل. إذا حدث ھذا لطفلك ، یجب علیك الاتصال بالقابلة و / أو طبیب على الفور. ً أثناء ۲٤ ً من حالات أخرى والتي تبدأ عادة قد یعاني طفلك أیضا ساعة الأولى من الولادة والتي تشمل الأعراض التالیة: ً أو □ مشكلة في التنفس □ ازرقاق الجلد، أو یصبح ساخن جدا بارد □ شفاه زرقاء □ قيء أو عدم تغذیة الجنین بشكل صحیح □ تعب الجنین بشكل شدید وعدم مقدرتھ على النوم أو البكاء بشدة □ تصلب أو مرونة العضلات □ رعاش، ارتعاش أو نوبات □ زیادة ردود الفعل العكسیة □ تھیج □ انخفاض السكر في الدم إذا كان لطفلك أي من ھذه الأعراض عند ولادتھ أو كنت تشعرین بالقلق حول صحة طفلك فإن علیك الاتصال بالطبیب أو القابلة الذین سیكونون قادرین على تقدیم النصیحة لك. ھناك أدلة على أن سیرترالین یمر في حلیب الأم. یجب استخدام سیرترالین أثناء الرضاعة فقط إذا اعتبر الطبیب بأن الفائدة من استخدامھ تفوق أي خطر محتمل للطفل. تبین في الدراسات الحیوانیة أن بعض الأدویة مثل سیرترالین قد تقلل نوعیة الحیوانات المنویة. ومن الناحیة النظریة، یمكن أن یؤثر ذلك على الخصوبة، ولكن لم یلاحظ حتى الآن التأثیر على الخصوبة البشریة. المعلومات الرصدیة تشیر إلى إزدیاد خطر حدوث نزیف ما بعد الولادة (أقل من ۲ ضعف) بعد التعرض لأدویة SNRI/SSRI خلال شھر قبل الولادة. تأثیر المستحضر على القیادة واستخدام الآلات: قد تؤثر الأدویة ذات التأثیر النفساني مثل السیرترالین على قدرتك في القیادة أو على استخدام الآلات، لذلك لا یجب أن تقود أو تستخدم الآلات حتى تتعرف على تأثیر ھذا الدواء على قدرتك في إنجاز ھذه الأنشطة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>□ دائما .ً □ تحقق من طبیبك أو الصیدلي إذا لم تكن متاكدا الجرعة التي ینصح بھا للبالغین: □ الاكتئاب واضطراب الوسواس القھري: الجرعة الاعتیادیة الفعالة لمعالجة الاكتئاب والوسواس القھري ٥۰ ملغم/یوم. یمكن زیادة الجرعة الیومیة بمقدار ٥۰ ملغم خلال فترة لا تقل عن أسبوع واحد على مدى أسابیع. الجرعة القصوى الموصى بھا ھي ۲۰۰ ملغم/ یوم. □ اضطراب الھلع واضطراب القلق الاجتماعي و اضطراب ما بعد الصدمة: یجب أن تبدأ المعالجة لاضطراب الھلع واضطراب القلق الاجتماعي واضطراب ما بعد الصدمة بجرعة ۲٥ ملغم/ یوم، وتزداد إلى ٥۰ ملغم/ یوم بعد أسبوع واحد، ثم یمكن زیادة الجرعة الیومیة بمقدار ٥۰ ملغم على مدى أسابیع. الجرعة القصوى الموصى بھا ھي ۲۰۰ ملغم/یوم. الاستخدام في الأطفال والمراھقین: یجب استخدام سیترال فقط للأطفال والمراھقین الذین تتراوح أعمارھم ما بین ٦ و ۱۷ سنة لعلاج الوسواس القھري. اضطراب الوسواس القھري: □ الأطفال الذین تتراوح أعمارھم من ٦ إلى ۱۲ سنة: جرعة ً. قد یزید لك الطبیب البدء الموصى بھا ھي ۲٥ ملغم یومیا ً. الجرعة الجرعة بعد أسبوع واحد لتصل إلى ٥۰ ملغم یومیا .ً القصوى الموصى بھا ھي ۲۰۰ ملغم یومیا □ المراھقین الذین تتراوح أعمارھم من ۱۳ إلى ۱۷ سنة: جرعة ً. الجرعة القصوى الموصى البدء الموصى بھا ھي ٥۰ ملغم یومیا .ً بھا ھي ۲۰۰ ملغم یومیا یرجى إخبار طبیبك واتباع تعلیماتھ إذا كنت تعاني من مشاكل في الكبد أو الكلى. طریقة الإعطاء: □ یمكن تناول اقراص سیترال مع أو بدون الطعام □ تناول دوائك مرة واحدة في الیوم سواء في الصباح أو المساء سینصحك طبیبك عن المدة التي یجب أن تتناول فیھا الدواء، وھذا یعتمد على طبیعة مرضك وعلى استجابتك للعلاج، فقد تحتاج إلى عدة أسابیع قبل أن تبدأ الأعراض بالتحسن. علاج الاكتئاب یجب ً إلى ٦ أشھر بعد التحسن. أن یستمرعادة الجرعة الزائدة من سیترال: اتصل بطبیبك على الفور أو اذھب إلى أقرب قسم طوارئ إذا تناولت عن غیر قصد كمیة كبیرة من ً خذ معك علبة الدواء سواء كانت تحتوي على دواء سیترال. دائما أو لا. قد تشمل أعراض الجرعة الزائدة النعاس والغثیان والقيء، زیادة معدل ضربات القلب، رعاش، ھیاج، دوخة، وفي حالات نادرة فقدان الوعي. نسیان تناول سیترال: إذا نسیت أن تتناول الجرعة فلا تتناولھا، فقط علیك تناول الجرعة التالیة في وقتھا الصحیح. لا تتناول جرعة مضاعفة لتعویض الجرعة المنسیة. التوقف عن تناول سیترال: لا تتوقف عن تناول سیترال ما لم یخبرك طبیبك بذلك. سیقلل طبیبك جرعة سیترال بشكل تدریجي خلال عدة أسابیع، قبل التوقف عن تناول ھذا الدواء بشكل نھائي. ً إذا توقفت عن تناول الدواء بشكل مفاجىء فقد تواجھ أعراضا جانبیة مثل الدوخة، الخدر، اضطرابات في النوم، ھیاج أو القلق، صداع، الشعور بالمرض، المرض، رعاش. یرجى التحدث لطبیبك إذا واجھت أي من ھذه الأعراض الجانبیة أو أي أعراض أخرى أثناء التوقف عن تناول سیترال. اسأل طبیبك أو الصیدلي إذا كان لدیك أي أسئلة أخرى حول استعمال ھذا المستحضر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كغیره من الأدویة فإن سیترال قد یسبب أعراضا من أنھا لاتحدث للجمیع. ً. تعتمد الأعراض الغثیان ھو أكثر الأعراض الجانبیة شیوعا ً ما تختفي أو تقل مع استمرار العلاج. الجانبیة على الجرعة وعادة أخبر طبیبك على الفور، إذا واجھتك أي من الأعراض التالیة بعد تناول ھذا الدواء فإن ھذه الأعراض قد تكون خطیرة: □ إذا عانیت من طفح جلدي شدید الذي یسبب تقرحات (حمامى عدیدة الأشكال) (وھذا یمكن أن یؤثر على الفم واللسان). قد تكون ھذه علامات على حالة مرضیة تعرف بمتلازمة ستیفنز جونسون أو تقشر الأنسجة المتموتة البشرویة التسممي. سیوقف طبیبك العلاج في مثل ھذه الحالات. □ تفاعلات تحسسیة أو حساسیة والتي قد تشمل أعراض مثل طفح جلدي وحكة، مشاكل تنفسیة، صفیر عند التنفس، تورم الجفون، الوجھ أو الشفاه. □ إذا عانیت من ھیاج، ارتباك، إسھال، ارتفاع درجة الحرارة وضغط الدم، تعرق شدید وتسارع نبضات القلب وھذه ھي أعراض متلازمة السیروتونین. في حالات نادرة قد تحدث ھذه المتلازمة عند تناول أدویة معینة في الوقت نفسھ مع سیرترالین. قد یرغب طبیبك في وقف المعالجة. □ إذا عانیت من اصفرار في الجلد والعینین وھو ما قد یعني تلف في الكبد. □ إذا عانیت من أعراض الاكتئاب مع أفكار لإیذاء أو قتل نفسك (أفكار انتحاریة). □ إذا بدأت بالشعور بالأرق وعدم القدرة على الجلوس أو الوقوف دون حراك بعد البدء بتناول سیترال. یجب أن تخبر طبیبك إذا بدأت بالشعور في التململ. □ إذا عانیت من نوبة. □ إذا عانیت من نوبة ھوس (انظر إلى قسم ۲ &quot; الاحتیاطات عند استعمال سیترال&quot;). الأعراض الجانبیة التالیة التي ظھرت في التجارب السریریة وبعد التسویق على البالغین: ً (قد تؤثر على أكثر من شخص الأعراض الجانبیة الشائعة جدا من ۱۰ أشخاص): أرق، دوخة، نعاس، صداع، إسھال، الشعور بالمرض، جفاف الفم، فشل القذف، تعب. الأعراض الجانبیة الشائعة (قد تؤثر على ما یصل إلى شخص واحد من ۱۰ أشخاص): □ نزلة صدریة، احتقان الحلق، سیلان الأنف □ قلة الشھیة، زیادة الشھیة □ قلق، اكتئاب، ھیاج، انخفاض الاھتمام الجنسي، توتر، الشعور بالغرابة، كابوس، صریر الأسنان □ اھتزاز، ً، توتر العضلات، مشاكل في الحركة العضلیة (مثل الحركة كثیرا صعوبة في المشي والتصلب، تشنجات وحركات لا إرادیة للعضلات) *، خدر ووخز، توتر عضلي، قلة الانتباه، طعم غیر طبیعي □ اضطرابات بصریة □ رنین في الأذنین □ خفقان □ ھبات ساخنة □ تثاءب □اضطراب المعدة، إمساك، آلام في البطن، تقیؤ، غازات □ زیادة التعرق والطفح الجلدي □ آلام الظھر، آلام المفاصل، آلام العضلات □ عدم انتظام الدورة الشھریة، ضعف الانتصاب □ الشعور بالضیق، ألم في الصدر، ضعف، حمى □ زیادة الوزن □ إصابة الأعراض الجانبیة الغیر الشائعة (قد تؤثر على ما یصل إلى شخص واحد من ۱۰۰ شخص): □ التھاب المعدة والأمعاء، التھاب الأذن □ ورم □ فرط الحساسیة، حساسیة موسمیة □ انخفاض ھرمونات الغدة الدرقیة □أفكار انتحاریة، سلوك انتحاري *، اضطراب ذھاني، تفكیر غیر طبیعي، نقص في الإھتمام، ھلوسة، عدوانیة، مزاج مبھج، جنون العظمة □ فقدان الذاكرة، انخفاض الشعور، ً، الصداع تقلصات العضلات اللاإرادیة، الإغماء، التحرك كثیرا النصفي، تشنج ، دوخة أثناء الوقوف، التنسیق غیر الطبیعي، اضطراب الكلام □ توسع البؤبؤ □ ألم الأذن □ سرعة ضربات القلب، مشكلة في القلب □ مشاكل النزیف (مثل نزیف المعدة) *، ارتفاع ضغط الدم، توھج، دم في البول □ ضیق في التنفس، نزیف من الأنف، صعوبة في التنفس، صفیر محتمل □ لون البراز مثل القطران، مشاكل الأسنان، التھاب المريء، مشكلة في اللسان، بواسیر، زیادة اللعاب، صعوبة البلع، التجشؤ، اضطراب في اللسان □ تورم العین، شرى، تساقط الشعر، حكة، بقع أرجوانیة على الجلد، مشكلة في الجلد مع بثور، جفاف الجلد، وذمة الوجھ، العرق البارد □ ھشاشة العظام، ارتعاش العضلات، تشنجات العضلات، ضعف العضلات □ زیادة في عدد مرات التبول، مشكلة في التبول عدم القدرة على التبول، سلس البول، زیادة التبول، التبول اللیلي □ الخلل الجنسي، النزیف المھبلي المفرط، النزیف المھبلي، الخلل الجنسي الأنثوي □ تورم في الساقین، قشعریرة، صعوبة في المشي، عطش □ زیادة في مستویات انزیمات الكبد، انخفاض الوزن □ تم الإبلاغ عن حالات التفكیر الانتحاري والسلوكیات الانتحاریة أثناء العلاج بإستخدام سیرترالین أو في وقت مبكر بعد التوقف عن العلاج (انظر القسم .(۲ الأعراض الجانبیة النادرة (قد تؤثر على ما یصل إلى شخص واحد من ۱۰۰۰ شخص): □ التھاب الرتج، تورم الغدد اللمفاویة، انخفاض خلایا التخثر *، انخفاض خلایا الدم البیضاء* □ رد فعل تحسسي شدید □ مشاكل الغدد الصماء * □ ارتفاع نسبة الكولیسترول، مشاكل في التحكم في مستویات السكر في الدم (السكري)، انخفاض نسبة السكر في الدم، زیادة مستویات السكر في الدم *، انخفاض مستوى الأملاح في الدم * □ أعراض جسدیة بسبب الإجھاد أو العواطف، أحلام مرعبة غیر طبیعیة *، الاعتماد على المخدرات، المشي أثناء النوم، القذف المبكر □ غیبوبة، حركات غیر طبیعیة، صعوبة في الحركة، زیادة الإحساس، صداع حاد مفاجئ (قد یكون علامة على حالة خطیرة تعرف باسم متلازمة تضیق الأوعیة الدماغیة العكسیة (RCVS ،* ((اضطراب حسي □ بقع أمام العین، ارتفاع ضغط العین، الرؤیة المزدوجة، الضوء یؤذي العین، دم في العین، بؤبؤ العینین غیر المتساویین الحجم *، الرؤیة غیر طبیعیة *، مشكلة في الدمع □ نوبة قلبیة، دوار خفیف، إغماء، انزعاج في الصدر یمكن أن یكون علامات على تغیرات في النشاط الكھربائي (یظھر على مخطط كھربیة القلب) أو إیقاع غیر طبیعي في القلب *، أو بطء ضربات القلب □ ضعف الدورة الدمویة في الذراعین والساقین □ التنفس السریع، التندب التدریجي لأنسجة الرئة (مرض الرئة الخلالي) *، إغلاق الحلق، صعوبة في الكلام، التنفس البطيء، حازوقة □ تقرح الفم، التھاب البنكریاس *، دم في البراز، تقرح اللسان، التھاب الفم □ مشاكل في وظائف الكبد، مشاكل خطیرة في وظائف الكبد *، اصفرار الجلد والعینین (الیرقان) * □ تفاعل الجلد مع الشمس *، وذمة الجلد *، ملمس غیر طبیعي للشعر، رائحة الجلد غیر طبیعیة، طفح الشعر □ انھیار أنسجة العضلات *، اضطراب العظام □ تردد البول، انخفاض التبول □ إفرازات الثدي، جفاف منطقة المھبل، إفرازات الأعضاء التناسلیة، إحمرار القضیب والقلفة المؤلم، تضخم الثدي *، الانتصاب لفترات طویلة □ فتق، انخفض تحمل الدواء □ زیادة مستویات الكولیسترول في الدم، الاختبارات المعملیة غیر الطبیعیة *، السائل المنوي غیر الطبیعي، مشاكل التخثر* □ استرخاء الأوعیة الدمویة. أعراض جانبیة غیر معروفة: لا یمكن تقدیر تكرار حدوثھا من البیانات المتاحة: □ الكزاز* □ التبول اللاإرادي* □ فقدان جزئي للرؤیة □ التھاب القولون (یسبب اسھال). □ نزیف مھبلي غزیر بعد الولادة بفترة وجیزة (نزیف ما بعد الولادة)، انظر قسم ۲ الحمل، الرضاعة الطبیعیة والخصوبة لمزید من المعلومات * * أعراض جانبیة تم الإبلاغ عنھا بعد التسویق. أعراض جانبیة إضافیة في الأطفال والمراھقین: الأعراض الجانبیة التي ظھرت في التجارب السریریة على الأطفال والمراھقین كانت مشابھة بشكل عام للأعراض التي ظھرت على ً في البالغین (انظر أعلاه). الأعراض الجانبیة الأكثر شیوعا الأطفال والمراھقین ھي صداع، أرق، إسھال، والشعور بالمرض. الأعراض التي قد تحدث عند وقف المعالجة: قد تواجھ الأعراض الجانبیة التالیة إذا توقفت عن المعالجة بشكل مفاجيء مثل الدوخة، الخدر، اضطرابات النوم، ھیاج أو قلق، صداع، الشعور بالمرض، المرض، ورعاش (أنظر إلى قسم ۳ &quot; التوقف عن تناول سیترال&quot;). وقد لوحظ زیادة خطر الكسور العظمیة في المرضى الذین یتناولون ھذا النوع من الأدویة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>□ یحفظ بعیدا □ لا یحفظ بدرجة حرارة أعلى من ۳۰&deg;م □ لا ینبغي استعمال سیترال بعد تاریخ انتھاء الصلاحیة الموجود على العلبة وعلى شریط الدواء. لا ینبغي التخلص من الأدویة من خلال میاه الصرف الصحي أو المنزلي. اسأل الصیدلاني عن كیفیة التخلص من الأدویة التي ل</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>□ المادة الفعالة ھي سیرترالین. كل قرص مغلف من أقراص سیترال٥۰ و ۱۰۰ یحتوي على ٥۰ و ۱۰۰ ملغم من سیرترالین على التوالي، على ھیئة سیرترالین ھیدروكلوراید. □ المكونات الأخرى ھي: سلیولوز بلوري مكروي ٥۰ میكرومیتر، فسفات ھیدروجین الكالسیوم اللامائیة، جلیكولات نشا الصودیوم (نوع A ،(ھیدروكسي بروبیل سلیولوز، ستیارات المغنیزیوم، ھیدروكسي بروبیل میثیل سلیولوز ۲۹۱۰ ،بولي إیثیلین جلایكول ٤۰۰ ،ثاني أكسید التیتانیوم، شمع العسل الأبیض</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>□ أقراص سیترال ٥۰ ھي أقراص مغلفة بیضاء إلى سكریة اللون دائریة ضحلة ثنائیة التحدب منقوش علیھا &ldquo;SL50 &rdquo;من جانب واحد و غیر منقوشة من الجانب الآخر. □ أقراص سیترال ۱۰۰ ھي أقراص مغلفة بیضاء إلى سكریة اللون بیضویة ثنائیة التحدب منقوش علیھا &ldquo;SL100 &rdquo;من جانب واحد و غیر منقوشة من الجانب الآخر. □ علب تحتوي على ۱۰ أقراص من سیترال ٥۰ محفوظة في أشرطة. □ علب تحتوي على ۳۰ قرص من سیترال ٥۰ محفوظة في أشرطة. □ علب تحتوي على ۱۰۰۰ قرص من سیترال ٥۰ محفوظة في أشرطة. □ علب تحتوي على ۱۰ أقراص من سیترال ۱۰۰ محفوظة في أشرطة. □ علب تحتوي على ۱۰۰۰ قرص من سیترال ۱۰۰ محفوظة في أشرطة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>الشركة الاردنية الانتاج الادوية&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ايلول 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SETRAL 100 mg Film-Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active ingredient:

 100 mg Sertraline film-coated tablets

Inactive ingredients:

Ingredient	Quantity
mg/tab.
Microcrystalline Cellulose 50 micrometer	106.01
Anhydrous Calcium Hydrogen Phosphate	30.38
Sodium Starch Glycolate (Type A)	19.99
Hydroxypropyl Cellulose (Klucel EF)	7.00
Magnesium Stearate	1.96
Hydroxypropyl Methylcellulose Type 2910 
(Methocel E5) 	6.61
Polyethylene Glycol 400	0.67
Titanium Dioxide	2.73
White Beeswax	Polish
Purified water	----

      *For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SETRAL 100 mg is White to off white, oval biconvex film coated tablet debossed with “SL 100” on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1-1&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</p><p>SETRAL is indicated for the treatment of:</p><p>&sect;&nbsp; Major depressive episodes. Prevention of recurrence of major depressive episodes.</p><p>&sect;&nbsp; Panic disorder, with or without agoraphobia.</p><p>&sect;&nbsp; Obsessive compulsive disorder (OCD) in adults and paediatric patients aged 6-17 years.</p><p>&sect;&nbsp; Social anxiety disorder.</p><p>&sect;&nbsp; Post traumatic stress disorder (PTSD).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp; &nbsp; &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Initial treatment</u></p><p>&sect;&nbsp; Depression and OCD</p><p>Sertraline treatment should be started at a dose of 50 mg/day.</p><p>&sect;&nbsp; Panic Disorder, PTSD, and Social Anxiety Disorder</p><p>Therapy should be initiated at 25 mg/day. After one week, the dose should be increased to 50 mg once daily. This dosage regimen has been shown to reduce the frequency of early treatment emergent side effects characteristic of panic disorder.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;<u>Titration</u></p><p>&sect;&nbsp; Depression, OCD, Panic Disorder, Social Anxiety Disorder and PTSD</p><p>Patients not responding to a 50 mg dose may benefit from dose increases. Dose changes should be made in steps of 50 mg at intervals of at least one week, up to a maximum of 200 mg/day. Changes in dose should not be made more frequently than once per week given the 24-hour elimination half life of Sertraline.</p><p>The onset of therapeutic effect may be seen within 7 days. However, longer periods are usually necessary to demonstrate therapeutic response, especially in OCD.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<u>Maintenance</u></p><p>Dosage during long-term therapy should be kept at the lowest effective level, with subsequent adjustment depending on therapeutic response.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&sect;&nbsp; Depression</p><p>Longer-term treatment may also be appropriate for prevention of recurrence of major depressive episodes (MDE). In most of the cases, the recommended dose in prevention of recurrence of MDE is the same as the one used during current episode. Patients with depression should be treated for a sufficient period of time of at least 6 months to ensure they are free from symptoms.</p><p>&sect;&nbsp; Panic disorder and OCD</p><p>Continued treatment in panic disorder and OCD should be evaluated regularly, as relapse prevention has not been shown for these disorders.</p><p><u>Elderly patients </u></p><p>Elderly should be dosed carefully, as elderly may be more at risk for hyponatraemia (see section 4.4).</p><p><u>Patients with hepatic impairment</u></p><p>The use of Sertraline in patients with hepatic disease should be approached with caution. A lower or less frequent dose should be used in patients with hepatic impairment (see section 4.4). Sertraline should not be used in cases of severe hepatic impairment as no clinical data are available (see section 4.4)</p><p><u>Patients with renal impairment</u></p><p>No dosage adjustment is necessary in patients with renal impairment (see section 4.4).</p><p><u>Paediatric population </u></p><p>Children and adolescents with obsessive compulsive disorder</p><p>&sect;&nbsp; Age 13-17 years: Initially 50 mg once daily.</p><p>&sect;&nbsp; Age 6-12 years: Initially 25 mg once daily. The dosage may be increased to 50 mg once daily after one week.</p><p>Subsequent doses may be increased in case of less than desired response in 50 mg increments over a period of some weeks, as needed. The maximum dosage is 200 mg daily. However, the generally lower body weights of children compared to those of adults should be taken into consideration when increasing the dose from 50 mg. Dose changes should not occur at intervals of less than one week.</p><p>Efficacy is not shown in paediatric major depressive disorder.</p><p>No data is available for children under 6 years of age (see also section 4.4).</p><p><u>Method of administration</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sertraline should be administered once daily, either in the morning or &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; evening.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sertraline tablet can be administered with or without food.</p><p>&nbsp;</p><p><u>Withdrawal symptoms seen on discontinuation of Sertraline</u></p><p>Abrupt discontinuation should be avoided. When stopping treatment with Sertraline the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substance or any of the excipients listed in section 6.1.
	Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia. Sertraline must not be initiated for at least 14 days after discontinuation of treatment with an irreversible MAOI. Sertraline must be discontinued for at least 7 days before starting treatment with an irreversible MAOI (see section 4.5). 
	Concomitant intake of pimozide is contraindicated (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>q&nbsp; Serotonin Syndrome (SS) or Neuroleptic Malignant Syndrome (NMS)</p><p>&nbsp;</p><p>The development of potentially life-threatening syndromes like serotonin syndrome (SS) or Neuroleptic Malignant Syndrome (NMS) has been reported with SSRIs, including treatment with Sertraline. The risk of SS or NMS with SSRIs is increased with concomitant use of serotonergic drugs (including triptans), with drugs which impair metabolism of serotonin (including MAOIs e.g. methylene blue), antipsychotics and other dopamine antagonists. Patients should be monitored for the emergence of signs and symptoms of SS or NMS syndrome (see section 4.3).</p><p>&nbsp;</p><p>q&nbsp; Switching from Selective Serotonin Reuptake Inhibitors (SSRIs), antidepressants or anti-obsessional drugs</p><p>&nbsp;</p><p>There is limited controlled experience regarding the optimal timing of switching from SSRIs, antidepressants or anti-obsessional drugs to Sertraline. Care and prudent medical judgment should be exercised when switching, particularly from long-acting agents such as fluoxetine.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>q&nbsp; Other serotonergic drugs e.g. tryptophan, fenfluramine and 5-HT agonists</p><p>&nbsp;</p><p>Co-administration of Sertraline with other drugs which enhance the effects of serotonergic neurotransmission such as tryptophan or fenfluramine or 5-HT agonists, or the herbal medicine, St John&#39;s Wort (hypericum perforatum), should be undertaken with caution and avoided whenever possible due to the potential for a pharmacodynamic interaction.</p><p>&nbsp;</p><p>&nbsp;</p><p>q&nbsp; QTc Prolongation/Torsade de Pointes (TdP)</p><p>&nbsp;</p><p>Cases of QTc prolongation and TdP have been reported during post-marketing use of sertraline. The majority of reports occurred in patients with other risk factors for QTc prolongation/TdP. Effect on QTc prolongation was confirmed in a thorough QTc study in healthy volunteers, with a statistically significant positive exposure response</p><p>relationship. Therefore, sertraline should be used with caution in patients with additional risk factors for QTc prolongation such as cardiac disease, hypokalaemia or hypomagnesemia, familial history of QTc prolongation, bradycardia and concomitant use of medications which prolong QTc interval (see sections 4.5 and 5.1).</p><p>&nbsp;</p><p>q&nbsp; Activation of hypomania or mania</p><p>&nbsp;</p><p>Manic/hypomanic symptoms have been reported to emerge in a small proportion of patients treated with marketed antidepressant and anti-obsessional drugs, including Sertraline. Therefore, Sertraline should be used with caution in patients with a history of mania/hypomania. Close surveillance by the physician is required. Sertraline should be discontinued in any patient entering a manic phase.</p><p>&nbsp;</p><p>q&nbsp; Schizophrenia</p><p>&nbsp;</p><p>Psychotic symptoms might become aggravated in schizophrenic patients.</p><p>&nbsp;</p><p>q&nbsp; Seizures</p><p>&nbsp;</p><p>Seizures may occur with Sertraline therapy: Sertraline should be avoided in patients with unstable epilepsy and patients with controlled epilepsy should be carefully monitored. Sertraline should be discontinued in any patient who develops seizures.</p><p>&nbsp;</p><p>q&nbsp; Suicide/suicidal thoughts/suicide attempts or clinical worsening</p><p>&nbsp;</p><p>Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>&nbsp;</p><p>Other psychiatric conditions, for which Sertraline is prescribed, can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p>&nbsp;</p><p>Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.</p><p>&nbsp;</p><p>Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p>&nbsp;</p><p>q&nbsp; Sexual dysfunction</p><p>&nbsp;</p><p>Selective serotonin reuptake inhibitors (SSRIs) may cause symptoms of sexual dysfunction (see section 4.8). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs.</p><p>&nbsp;</p><p>q&nbsp; Paediatrec population</p><p>&nbsp;</p><p>Sertraline should not be used in the treatment of children and adolescents under the age of 18 years, except for patients with obsessive compulsive disorder aged 6-17 years old. Suicide-related behaviours (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken; the patient should be carefully monitored for appearance of suicidal symptoms. In addition only limited clinical evidence is available concerning, long-term safety data in children and adolescents including effects on growth, sexual maturation and cognitive and behavioural developments. A few cases of retarded growth and delayed puberty have been reported post-marketing. The clinical relevance and causality are yet unclear (see section 5.3 for corresponding preclinical safety data). Physicians must monitor paediatric patients on long term treatment for abnormalities in growth and development.</p><p>&nbsp;</p><p>q&nbsp; Abnormal bleeding/Haemorrhage</p><p>&nbsp;</p><p>There have been reports of bleeding abnormalities with SSRIs including cutaneous bleeding (ecchymoses and purpura) and other haemorrhagic events such as gastrointestinal or gynaecological bleeding, including fatal haemorrhages. Caution is advised in patients taking SSRIs, particularly in concomitant use with drugs known to affect platelet function (e.g. anticoagulants, atypical antipsychotics and phenothiazines, most tricyclic antidepressants, acetylsalicylic acid and non-steroidal anti-inflammatory drugs (NSAIDs)) as well as in patients with a history of bleeding disorders (see section 4.5).</p><p>&nbsp;</p><p>q&nbsp; Hyponatraemia</p><p>&nbsp;</p><p>Hyponatraemia may occur as a result of treatment with SSRIs or SNRIs including Sertraline. In many cases, hyponatraemia appears to be the result of a syndrome of inappropriate antidiuretic hormone secretion (SIADH). Cases of serum sodium levels lower than 110 mmol/l have been reported.</p><p>&nbsp;</p><p>Elderly patients may be at greater risk of developing hyponatraemia with SSRIs and SNRIs. Also patients taking diuretics or who are otherwise volume-depleted may be at greater risk (see Use in elderly). Discontinuation of Sertraline should be considered in patients with symptomatic hyponatraemia and appropriate medical intervention should be instituted. Signs and symptoms of hyponatraemia include headache, difficulty concentrating, memory impairment, confusion, weakness and unsteadiness which may lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.</p><p>&nbsp;</p><p>q&nbsp; Withdrawal symptoms seen on discontinuation of Sertraline treatment</p><p>&nbsp;</p><p>Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials, among patients treated with Sertraline, the incidence of reported withdrawal reactions was 23% in those discontinuing Sertraline compared to 12% in those who continued to receive Sertraline treatment.</p><p>&nbsp;</p><p>The risk of withdrawal symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported reactions. Generally these symptoms are mild to moderate; however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose. Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that Sertraline should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&#39;s needs (see section 4.2).</p><p>&nbsp;</p><p>q&nbsp; Akathisia/psychomotor restlessness</p><p>&nbsp;</p><p>The use of Sertraline has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p>&nbsp;</p><p>&nbsp;</p><p>q&nbsp; Hepatic impairment</p><p>&nbsp;</p><p>Sertraline is extensively metabolised by the liver. A multiple dose pharmacokinetic study in subjects with mild, stable cirrhosis demonstrated a prolonged elimination half life and approximately three-fold greater AUC and Cmax in comparison to normal subjects. There were no significant differences in plasma protein binding observed between the two groups. The use of Sertraline in patients with hepatic disease must be approached with caution. If Sertraline is administered to patients with hepatic impairment, a lower or less frequent dose should be considered. Sertraline should not be used in patients with severe hepatic impairment (see section 4.2).</p><p>&nbsp;</p><p>q&nbsp; Renal impairment</p><p>&nbsp;</p><p>Sertraline is extensively metabolised, and excretion of unchanged drug in urine is a minor route of elimination. In studies of patients with mild to moderate renal impairment (creatinine clearance 30-60 ml/min) or moderate to severe renal impairment (creatinine clearance 10-29 ml/min), multiple-dose pharmacokinetic parameters (AUC0-24 or Cmax) were not significantly different compared with controls. Sertraline dosing does not have to be adjusted based on the degree of renal impairment.</p><p>&nbsp;</p><p>q&nbsp; Use in elderly</p><p>&nbsp;</p><p>Over 700 elderly patients (&gt;65 years) have participated in clinical studies. The pattern and incidence of adverse reactions in the elderly was similar to that in younger patients.</p><p>&nbsp;</p><p>SSRIs or SNRIs including Sertraline have however been associated with cases of clinically significant hyponatraemia in elderly patients, who may be at greater risk for this adverse event (see Hyponatraemia in section 4.4).</p><p>&nbsp;</p><p>q&nbsp; Diabetes</p><p>&nbsp;</p><p>In patients with diabetes, treatment with an SSRI may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted.</p><p>&nbsp;</p><p>q&nbsp; Electroconvulsive therapy</p><p>&nbsp;</p><p>There are no clinical studies establishing the risks or benefits of the combined use of ECT and Sertraline.</p><p>&nbsp;</p><p>q&nbsp; Grapefruit juice</p><p>&nbsp;</p><p>The administration of Sertraline with grapefruit juice is not recommended (see section 4.5).</p><p>&nbsp;</p><p>q&nbsp; Interference with urine screening tests</p><p>&nbsp;</p><p>False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking Sertraline. This is due to lack of specificity of the screening tests. False-positive test results may be expected for several days following discontinuation of Sertraline therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish Sertraline from benzodiazepines.</p><p>&nbsp;</p><p>q&nbsp; Angle-Closure Glaucoma</p><p>&nbsp;</p><p>SSRIs including Sertraline may have an effect on pupil size resulting in mydriasis. This mydriatic effect has the potential to narrow the eye angle resulting in increased intraocular pressure and angle-closure glaucoma, especially in patients pre-disposed. Sertraline should therefore be used with caution in patients with angle-closure glaucoma or history of glaucoma.</p><p>&nbsp;</p><p>- SSRIs/ SNRIs may increase the risk of postpartum hemorrhage</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Contraindicated</u></p><p><u>&nbsp;</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Monoamine Oxidase Inhibitors</em></p><p><em>&nbsp;</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irreversible MAOIs (e.g. selegiline)</em></p><p>&nbsp;</p><p>Sertraline must not be used in combination with irreversible MAOIs such as selegiline. Sertraline must not be initiated for at least 14 days after discontinuation of treatment with an irreversible MAOI. Sertraline must be discontinued for at least 7 days before starting treatment with an irreversible MAOI (see section 4.3).</p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reversible, selective MAO-A inhibitor (moclobemide)</em></p><p>&nbsp;</p><p>Due to the risk of serotonin syndrome, the combination of Sertraline with a reversible and selective MAOI, such as moclobemide, should not be given. Following treatment with a reversible MAO-inhibitor, a shorter withdrawal period than 14 days may be used before initiation of Sertraline treatment. It is recommended that Sertraline should be discontinued for at least 7 days before starting treatment with a reversible MAOI (see section 4.3).</p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reversible, non-selective MAOI (linezolid)</em></p><p>&nbsp;</p><p>The antibiotic linezolid is a weak reversible and non-selective MAOI and should not be given to patients treated with Sertraline (see section 4.3).</p><p>Severe adverse reactions have been reported in patients who have recently been discontinued from an MAOI (e.g. methylene blue) and started on Sertraline or have recently had Sertraline therapy discontinued prior to initiation of an MAOI. These reactions have included tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, and hyperthermia with features resembling neuroleptic malignant syndrome, seizures, and death.</p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pimozide</em></p><p>&nbsp;</p><p>Increased pimozide levels of approximately 35% have been demonstrated in a study of a single low dose pimozide (2 mg). These increased levels were not associated with any changes in EKG. While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide, concomitant administration of Sertraline and pimozide is contraindicated (see section 4.3).</p><p>&nbsp;</p><p>Co-administration with Sertraline is not recommended</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>CNS depressants and alcohol</em></p><p>&nbsp;</p><p>The co-administration of Sertraline 200 mg daily did not potentiate the effects of alcohol, carbamazepine, haloperidol, or phenytoin on cognitive and psychomotor performance in healthy subjects; however, the concomitant use of Sertraline and alcohol is not recommended.</p><p><em>&nbsp;</em></p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other serotonergic drugs</em></p><p><em>&nbsp;</em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See section 4.4.</p><p>&nbsp;</p><p>Caution is also advised with fentanyl used in general anaesthesia or in the treatment of chronic pain, other serotonergic drugs (including other serotonergic antidepressants triptans) and with other opiate drugs.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Special Precautions</u></p><p><u>&nbsp;</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Drugs that Prolong the QT Interval</em><strong><em> </em></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The risk of QTc prolongation and/or ventricular arrhythmias (e.g. TdP) &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; may be increased with concomitant use of other drugs which prolong the</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; QTc interval (e.g. some antipsychotics and antibiotics) (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;<em>Lithium</em></p><p>&nbsp;</p><p>In a placebo-controlled trial in normal volunteers, the co-administration of Sertraline with lithium did not significantly alter lithium pharmacokinetics, but did result in an increase in tremor relative to placebo, indicating a possible pharmacodynamic interaction. When co-administering Sertraline with lithium, patients should be appropriately monitored.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>&nbsp;Phenytoin</em></p><p>&nbsp;</p><p>A placebo-controlled trial in normal volunteers suggests that chronic administration of Sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism. Nonetheless, as some case reports have emerged of high phenytoin exposure in patients using Sertraline, it is recommended that plasma phenytoin concentrations be monitored following initiation of Sertraline therapy, with appropriate adjustments to the phenytoin dose. In addition, co-administration of phenytoin may cause a reduction of Sertraline plasma levels. It cannot be excluded that other CYP3A4 inducers, e.g. phenobarbital, carbamazepine, St John&#39;s Wort, rifampicin may cause a reduction of Sertraline plasma levels.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Triptans</em></p><p>&nbsp;</p><p>There have been rare post-marketing reports describing patients with weakness, hyperreflexia, incoordination, confusion, anxiety and agitation following the use of Sertraline and sumatriptan. Symptoms of serotonergic syndrome may also occur with other products of the same class (triptans). If concomitant treatment with Sertraline and triptans is clinically warranted, appropriate observation of the patient is advised (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Warfarin</em></p><p>&nbsp;</p><p>Co-administration of Sertraline 200 mg daily with warfarin resulted in a small but statistically significant increase in prothrombin time, which may in some rare cases unbalance the INR value.</p><p>&nbsp;</p><p>Accordingly, prothrombin time should be carefully monitored when Sertraline therapy is initiated or stopped.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other drug interactions, digoxin, atenolol, cimetidine</em></p><p>&nbsp;</p><p>Co-administration with cimetidine caused a substantial decrease in Sertraline clearance. The clinical significance of these changes is unknown. Sertraline had no effect on the beta-adrenergic blocking ability of atenolol. No interaction of Sertraline 200 mg daily was observed with digoxin.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Drugs affecting platelet function</em></p><p>&nbsp;</p><p>The risk of bleeding may be increased when medicines acting on platelet function (e.g. NSAIDs, acetylsalicylic acid and ticlopidine) or other medicines that might increase bleeding risk are concomitantly administered with SSRIs, including Sertraline (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neuromuscular Blockers </em></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SSRIs may reduce plasma cholinesterase activity resulting in a &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prolongation of the neuromuscular blocking action of mivacurium or</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other neuromuscular blockers.</p><p>&nbsp;</p><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs Metabolized by Cytochrome P450</em></p><p>&nbsp;</p><p>Sertraline may act as a mild-moderate inhibitor of CYP 2D6. Chronic dosing with Sertraline 50 mg daily showed moderate elevation (mean 23%-37%) of steady-state desipramine plasma levels (a marker of CYP 2D6 isozyme activity). Clinical relevant interactions may occur with other CYP 2D6 substrates with a narrow therapeutic index like class 1C antiarrhythmics such as propafenone and flecainide, TCAs and typical antipsychotics, especially at higher Sertraline dose levels.</p><p>&nbsp;</p><p>Sertraline does not act as an inhibitor of CYP 3A4, CYP 2C9, CYP 2C19, and CYP 1A2 to a clinically significant degree. This has been confirmed by in-vivo interaction studies with CYP3A4 substrates (endogenous cortisol, carbamazepine, terfenadine, alprazolam), CYP2C19 substrate diazepam, and CYP2C9 substrates tolbutamide, glibenclamide and phenytoin. In vitro studies indicate that Sertraline has little or no potential to inhibit CYP 1A2.</p><p>&nbsp;</p><p>Intake of three glasses of grapefruit juice daily increased the Sertraline plasma levels by approximately 100% in a cross-over study in eight Japanese healthy subjects. Therefore, the intake of grapefruit juice should be avoided during treatment with Sertraline (see section 4.4).</p><p>&nbsp;</p><p>Based on the interaction study with grapefruit juice, it cannot be excluded that the concomitant administration of Sertraline and potent CYP3A4 inhibitors, e.g. protease inhibitors, ketoconazole, itraconazole, posaconazole, voriconazole, clarithromycin, telithromycin and nefazodone, would result in even larger increases in exposure of Sertraline. This also concerns moderate CYP3A4 inhibitors, e.g. aprepitant, erythromycin, fluconazole, verapamil and diltiazem. The intake of potent CYP3A4 inhibitors should be avoided during treatment with Sertraline.</p><p>&nbsp;</p><p>Sertraline plasma levels are enhanced by about 50% in poor metabolizers of CYP2C19 compared to rapid metabolizers (see section 5.2). Interaction with strong inhibitors of CYP2C19, e.g. omeprazole, lansoprazole, pantoprazole, rabeprazole, fluoxetine, fluvoxamine cannot be excluded</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy</em></strong></p><p>There are no well controlled studies in pregnant women. However, a substantial amount of data did not reveal evidence of induction of congenital malformations by sertraline. Animal studies showed evidence for effects on reproduction probably due to maternal toxicity caused by the pharmacodynamic action of the compound and/or direct pharmacodynamic action of the compound on the foetus (see section 5.3).</p><p>Use of sertraline during pregnancy has been reported to cause symptoms, compatible with withdrawal reactions, in some neonates, whose mothers had been on sertraline. This phenomenon has also been observed with other SSRI antidepressants. Sertraline is not recommended in pregnancy, unless the clinical condition of the woman is such that the benefit of the treatment is expected to outweigh the potential risk.</p><p>Observational data indicate an increased risk (less than 2-fold) of postpartum haemorrhage following SSRI/SNRI exposure within the month prior to birth (see sections 4.4, 4.8).</p><p>Neonates should be observed if maternal use of sertraline continues into the later stages of pregnancy, particularly the third trimester. The following symptoms may occur in the neonate after maternal sertraline use in later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty in sleeping. These symptoms could be due to either serotonergic effects or withdrawal symptoms. In a majority of instances the complications begin immediately or soon (&lt;24 hours)&nbsp;after delivery.</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particular in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per 1000 pregnancies occur.</p><p>&nbsp;</p><p><strong><em>Breast-feeding</em></strong></p><p>Published data concerning sertraline levels in breast milk show that small quantities of sertraline and its metabolite N-desmethylsertraline are excreted in milk. Generally negligible to undetectable levels were found in infant serum, with one exception of an infant with serum levels about 50% of the maternal level (but without a noticeable health effect in this infant). To date, no adverse effects on the health of infants nursed by mothers using sertraline have been reported, but a risk cannot be excluded. Use in nursing mothers is not recommended unless, in the judgment of the physician, the benefit outweighs the risk.</p><p>&nbsp;</p><p><strong><em>Fertility</em></strong></p><p>Animal data did not show an effect of sertraline on fertility parameters (see section 5.3.).</p><p>Human case reports with some SSRI&#39;s have shown that an effect on sperm quality is reversible.</p><p>Impact on human fertility has not been observed so far.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical pharmacology studies have shown that Sertraline has no effect on psychomotor performance. However, as psychotropic drugs may impair the mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery, the patient should be cautioned accordingly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nausea is the most common undesirable effect. In the treatment of social anxiety disorder, sexual dysfunction (ejaculation failure) in men occurred in 14% for sertraline vs 0% in placebo. These undesirable effects are dose dependent and are often transient in nature with continued treatment.</p><p>The undesirable effects profile commonly observed in double-blind, placebo-controlled studies in patients with OCD, panic disorder, PTSD and social anxiety disorder was similar to that observed in clinical trials in patients with depression.</p><p>Table 1&nbsp;displays adverse reactions observed from post-marketing experience (frequency not known) and placebo-controlled clinical trials (comprising a total of 2542 patients on sertraline and 2145 on placebo) in depression, OCD, panic disorder, PTSD and social anxiety disorder.</p><p>Some adverse drug reactions listed in Table 1 may decrease in intensity and frequency with continued treatment and do not generally lead to cessation of therapy.</p><table border="1" cellspacing="0" cellpadding="0" style="width:628px"><tbody><tr><td colspan="6" style="vertical-align:top"><p><strong><em>Table 1: Adverse Reactions</em></strong></p><p><strong>Frequency of adverse reactions observed from placebo-controlled clinical trials in depression, OCD, panic disorder, PTSD and social anxiety disorder. Pooled analysis and post-marketing experience.</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very Common</strong></p><p><strong>(&ge;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>(&ge;1/100 to &lt;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge;1/1,000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(&ge;1/10,000 to &lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency Not Known (Cannot be Estimated From the Available Data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>upper respiratory tract infection,<em>&nbsp;</em>pharyngitis, rhinitis</p></td><td style="vertical-align:top"><p>gastroenteritis, otitis media</p></td><td style="vertical-align:top"><p>diverticulitis<sup>&sect;</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>neoplasm</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>lymphadenopathy, thrombocytopenia<sup>&lowast;</sup><sup>&sect;</sup>, leukopenia<sup>&lowast;</sup><sup>&sect;</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hypersensitivity<sup>&lowast;</sup>, seasonal allergy<sup>&lowast;</sup></p></td><td style="vertical-align:top"><p>anaphylactoid reaction<sup>&lowast;</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hypothyroidism<sup>&lowast;</sup></p></td><td style="vertical-align:top"><p>hyperprolactinaemia<sup>&lowast;</sup><sup>&sect;</sup>, inappropriate antidiuretic hormone secretion<sup>&lowast;</sup><sup>&sect;</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>decreased appetite, increased appetite<sup>&lowast;</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hypercholesterolaemia, diabetes mellitus<sup>&lowast;</sup>, hypoglycaemia<sup>&lowast;</sup>, hyperglycaemia<sup>&lowast;</sup><sup>&sect;</sup>, hyponatraemia<sup>&lowast;</sup><sup>&sect;</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>anxiety*, depression*, agitation*, libido decreased*, nervousness, depersonalisation, nightmare, bruxism*</p></td><td style="vertical-align:top"><p>suicidal ideation/behaviour, psychotic disorder<sup>&lowast;</sup>, thinking abnormal, apathy, hallucination*, aggression*, euphoric mood*, paranoia</p></td><td style="vertical-align:top"><p>conversion disorder<sup>&lowast;</sup><sup>&sect;</sup>, paroniria<sup>&lowast;</sup><sup>&sect;</sup>, drug dependence, sleep walking, premature ejaculation</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>dizziness, headache<sup>*,&nbsp;</sup>somnolence</p></td><td style="vertical-align:top"><p>tremor, movement disorders (including extrapyramidal symptoms such as hyperkinesia, hypertonia, dystonia, teeth grinding or gait abnormalities), paraesthesia*, hypertonia*, disturbance in attention, dysgeusia</p></td><td style="vertical-align:top"><p>amnesia, hypoaesthesia*, muscle contractions involuntary*, syncope*, hyperkinesia*, migraine*, convulsion*, dizziness postural, coordination abnormal, speech disorder</p></td><td style="vertical-align:top"><p>coma*, akathisia (see section 4.4), dyskinesia, hyperaesthesia, cerebrovascular spasm (including reversible cerebral vasoconstriction syndrome and Call-Fleming syndrome)<sup>&lowast;</sup><sup>&sect;</sup>, psychomotor restlessness<sup>&lowast;</sup><sup>&sect;</sup>&nbsp;(see section 4.4), sensory disturbance, choreoathetosis<sup>&sect;</sup>, also reported were signs and symptoms associated with serotonin syndrome<sup>&lowast;</sup>&nbsp;or neuroleptic malignant syndrome: In some cases associated with concomitant use of serotonergic drugs that included agitation, confusion, diaphoresis, diarrhoea, fever, hypertension, rigidity and tachycardia<sup>&sect;</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>visual disturbance<sup>&lowast;</sup></p></td><td style="vertical-align:top"><p>mydriasis<sup>&lowast;</sup></p></td><td style="vertical-align:top"><p>scotoma, glaucoma, diplopia, photophobia, hyphaema<sup>&lowast;</sup><sup>&sect;</sup>, pupils unequal<sup>&lowast;</sup><sup>&sect;</sup>, vision abnormal<sup>&sect;</sup>, lacrimal disorder</p></td><td style="vertical-align:top"><p>maculopathy</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>tinnitus<sup>&lowast;</sup></p></td><td style="vertical-align:top"><p>ear pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>palpitations<sup>&lowast;</sup></p></td><td style="vertical-align:top"><p>tachycardia<sup>&lowast;</sup>,<em>&nbsp;</em>cardiac disorder</p></td><td style="vertical-align:top"><p>myocardial infarction<sup>&lowast;</sup><sup>&sect;</sup>, Torsade de Pointes<sup>&lowast;</sup><sup>&sect;</sup>&nbsp;(see sections 4.4, 4.5 and 5.1), bradycardia, QTc prolongation<sup>&lowast;</sup>&nbsp;(see sections 4.4, 4.5 and 5.1)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hot flush<sup>&lowast;</sup></p></td><td style="vertical-align:top"><p>abnormal bleeding (such as gastrointestinal bleeding)<sup>&lowast;</sup>, hypertension<sup>&lowast;</sup>, flushing, haematuria<sup>&lowast;</sup></p></td><td style="vertical-align:top"><p>peripheral ischaemia</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>yawning<sup>&lowast;</sup></p></td><td style="vertical-align:top"><p>dyspnoea, epistaxis<sup>&lowast;</sup>, bronchospasm*</p></td><td style="vertical-align:top"><p>hyperventilation, interstitial lung disease<sup>&lowast;</sup><sup>&sect;</sup>, laryngospasm, dysphonia, stridor<sup>&lowast;</sup><sup>&sect;</sup>, hypoventilation, hiccups</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>nausea, diarrhoea, dry mouth</p></td><td style="vertical-align:top"><p>dyspepsia, constipation*, abdominal pain*, vomiting*, flatulence</p></td><td style="vertical-align:top"><p>melaena, tooth disorder, oesophagitis, glossitis, haemorrhoids, salivary hypersecretion, dysphagia, eructation, tongue disorder</p></td><td style="vertical-align:top"><p>mouth ulceration, pancreatitis<sup>&lowast;</sup><sup>&sect;</sup>, haematochezia, tongue ulceration, stomatitis</p></td><td style="vertical-align:top"><p>colitis microscopic*</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hepatic function abnormal, serious liver events (including hepatitis, jaundice and hepatic failure)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>hyperhidrosis, rash*</p></td><td style="vertical-align:top"><p>periorbital oedema*, urticaria*, alopecia*, pruritus*, purpura*, dermatitis, dry skin, face oedema, cold sweat</p></td><td style="vertical-align:top"><p>rare reports of severe cutaneous adverse reactions (SCAR): e.g. Stevens-Johnson syndrome<sup>&lowast;</sup>&nbsp;and epidermal necrolysis<sup>&lowast;</sup><sup>&sect;</sup>, skin reaction<sup>&lowast;</sup><sup>&sect;</sup>, photosensitivity<sup>&sect;</sup>, angioedema, hair texture abnormal, skin odour abnormal, dermatitis bullous, rash follicular</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>back pain, arthralgia<sup>&lowast;</sup>, myalgia</p></td><td style="vertical-align:top"><p>osteoarthritis, muscle twitching, muscle cramps<sup>&lowast;</sup>, muscular weakness</p></td><td style="vertical-align:top"><p>rhabdomyolysis<sup>&lowast;</sup><sup>&sect;</sup>, bone disorder</p></td><td style="vertical-align:top"><p>trismus*</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>pollakiuria, micturition disorder, urinary retention, urinary incontinence*, polyuria, nocturia</p></td><td style="vertical-align:top"><p>urinary hesitation*, oliguria</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>ejaculation failure</p></td><td style="vertical-align:top"><p>menstruation irregular<sup>&lowast;</sup>, erectile dysfunction</p></td><td style="vertical-align:top"><p>sexual dysfunction (see section 4.4), menorrhagia, vaginal haemorrhage, female sexual dysfunction (see section 4.4)</p></td><td style="vertical-align:top"><p>galactorrhoea*, atrophic vulvovaginitis, genital discharge, balanoposthitis<sup>&lowast;</sup><sup>&sect;</sup>, gynaecomastia<sup>&lowast;</sup>, priapism*</p></td><td style="vertical-align:top"><p>postpartum haemorrhage*<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>fatigue*</p></td><td style="vertical-align:top"><p>malaise*, chest pain*, asthenia<sup>&lowast;</sup>, pyrexia<sup>&lowast;</sup></p></td><td style="vertical-align:top"><p>oedema peripheral*, chills, gait disturbance<sup>&lowast;</sup>, thirst</p></td><td style="vertical-align:top"><p>hernia, drug tolerance decreased</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>weight increased<sup>&lowast;</sup></p></td><td style="vertical-align:top"><p>alanine aminotransferase increased*, aspartate aminotransferase increased*, weight decreased*</p></td><td style="vertical-align:top"><p>blood cholesterol increased<sup>&lowast;</sup>, abnormal clinical laboratory results, semen abnormal, altered platelet function<sup>&lowast;</sup><sup>&sect;</sup></p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>injury</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Surgical and medical procedures</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>vasodilation procedure</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>&lowast;</sup><sup>&nbsp;</sup>ADR identified post-marketing</p><p><sup>&sect;</sup>&nbsp;ADR frequency represented by the estimated upper limit of the 95% confidence interval using &ldquo;The Rule of 3&rdquo;.</p><p><sup>&dagger;</sup>&nbsp;This event has been reported for the therapeutic class of SSRIs/SNRIs (see sections 4.4, 4.6).</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Withdrawal symptoms seen on discontinuation of sertraline treatment</u></p><p>Discontinuation of sertraline (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported. Generally these events are mild to moderate and are self-limiting; however, in some patients they may be severe and/or prolonged. It is therefore advised that when sertraline treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see sections 4.2 and 4.4).</p><p><u>Elderly population</u></p><p>SSRIs or SNRIs including sertraline have been associated with cases of clinically significant hyponatraemia in elderly patients, who may be at greater risk for this adverse event (see section 4.4).</p><p><u>Paediatric population</u></p><p>In over 600 paediatric patients treated with sertraline, the overall profile of adverse reactions was generally similar to that seen in adult studies. The following adverse reactions were reported from controlled trials (n=281 patients treated with sertraline):</p><p>Very common (&ge;1/10): Headache (22%), insomnia (21%), diarrhoea (11%) and nausea (15%).</p><p>Common (&ge;1/100 to &lt;1/10): Chest pain, mania, pyrexia, vomiting, anorexia, affect lability, aggression, agitation, nervousness, disturbance in attention, dizziness, hyperkinesia, migraine, somnolence, tremor, visual disturbance, dry mouth, dyspepsia, nightmare, fatigue, urinary incontinence, rash, acne, epistaxis, flatulence.</p><p>Uncommon (&ge;1/1000 to &lt;1/100): ECG QT prolonged (see sections 4.4, 4.5 and 5.1), suicide attempt, convulsion, extrapyramidal disorder, paraesthesia, depression, hallucination, purpura, hyperventilation, anaemia, hepatic function abnormal, alanine aminotransferase increased, cystitis, herpes simplex, otitis externa, ear pain, eye pain, mydriasis, malaise, haematuria, rash pustular, rhinitis, injury, weight decreased, muscle twitching, abnormal dreams, apathy, albuminuria, pollakiuria, polyuria, breast pain, menstrual disorder, alopecia, dermatitis, skin disorder, skin odour abnormal, urticaria, bruxism, flushing.</p><p>Frequency not known: enuresis</p><p><u>Class effects</u></p><p>Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.</p><p>Saudi Arabia: To report any side effect(s): National Pharmacovigilance Center (NPC):&nbsp; Fax: +966-11-205-7662, SFDA Call center: 19999, E-mail: npc.drug@sfda.gov.sa, Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Toxicity</u></p><p>Sertraline has a margin of safety dependent on patient population and/or concomitant medication. Deaths have been reported involving overdoses of Sertraline, alone or in combination with other drugs and/or alcohol. Therefore, any overdosage should be medically treated aggressively.</p><p><u>Symptoms</u></p><p>Symptoms of overdose include serotonin-mediated side effects such as somnolence, gastrointestinal disturbances (such as nausea and vomiting), tachycardia, tremor, agitation and dizziness. Coma has been reported although less frequently.</p><p>QTc prolongation/Torsade de Pointes has been reported following sertraline overdose; therefore, ECG-monitoring is recommended in all ingestions of sertraline overdoses.</p><p><u>Managment</u></p><p>There are no specific antidotes to Sertraline. It is recommended to establish and maintain an airway and, if necessary, ensure adequate oxygenation and ventilation. Activated charcoal, which may be used with a cathartic, may be as, or more effective than lavage, and should be considered in treating overdose. Induction of emesis is not recommended. Cardiac (e.g. ECG) and vital sign monitoring is also recommended, along with general symptomatic and supportive measures. Due to the large volume of distribution of sertraline, forced diuresis, dialysis, haemoperfusion and exchange transfusion are unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;&nbsp;Pharmacotherapeutic group:<strong> </strong>Selective serotonin reuptake inhibitors (SSRI)</p><p><strong>&nbsp;&nbsp;</strong>ATC Code: N06 AB06</p><p><u>Mechanism of action</u></p><p>Sertraline is a potent and specific inhibitor of neuronal serotonin (5 HT) uptake in vitro, which results in the potentiation of the effects of 5-HT in animals. It has only very weak effects on norepinephrine and dopamine neuronal reuptake. At clinical doses, Sertraline blocks the uptake of serotonin into human platelets. It is devoid of stimulant, sedative or anticholinergic activity or cardiotoxicity in animals. In controlled studies in normal volunteers, Sertraline did not cause sedation and did not interfere with psychomotor performance. In accord with its selective inhibition of 5-HT uptake, Sertraline does not enhance catecholaminergic activity. Sertraline has no affinity for muscarinic (cholinergic), serotonergic, dopaminergic, adrenergic, histaminergic, GABA or benzodiazepine receptors. The chronic administration of Sertraline in animals was associated with down-regulation of brain norepinephrine receptors as observed with other clinically effective antidepressants and antiobsessional drugs.</p><p>Sertraline has not demonstrated potential for abuse. In a placebo-controlled, double-blind randomized study of the comparative abuse liability of Sertraline, alprazolam and d-amphetamine in humans, Sertraline did not produce positive subjective effects indicative of abuse potential. In contrast, subjects rated both alprazolam and d-amphetamine significantly greater than placebo on measures of drug liking, euphoria and abuse potential. Sertraline did not produce either the stimulation and anxiety associated with d-amphetamine or the sedation and psychomotor impairment associated with alprazolam. Sertraline does not function as a positive reinforcer in rhesus monkeys trained to self administer cocaine, nor does it substitute as a discriminative stimulus for either d-amphetamine or pentobarbital in rhesus monkeys.</p><p><u>Clinical efficacy and safety </u></p><p><em>Major Depressive Disorder</em></p><p>A study was conducted which involved depressed outpatients who had responded by the end of an initial 8-week open treatment phase on Sertraline 50-200 mg/day. These patients (n=295) were randomized to continuation for 44 weeks on double-blind Sertraline 50-200 mg/day or placebo. A statistically significantly lower relapse rate was observed for patients taking Sertraline compared to those on placebo. The mean dose for completers was 70 mg/day. The % of responders (defined as those patients that did not relapse) for Sertraline and placebo arms were 83.4% and 60.8%, respectively.</p><p><em>Post traumatic stress disorder (PTSD)</em></p><p>Combined data from the 3 studies of PTSD in the general population found a lower response rate in males compared to females. In the two positive general population trials, the male and female Sertraline vs. placebo responder rates were similar (females: 57.2% vs 34.5%; males: 53.9% vs 38.2%). The number of male and female patients in the pooled general population trials was 184 and 430, respectively and hence the results in females are more robust and males were associated with other baseline variables (more substance abuse, longer duration, source of trauma etc) which are correlated with decreased effect.</p><p><em>Cardiac Electrophysiology</em></p><p>In a dedicated thorough QTc study, conducted at steady state at supratherapeutic exposures in healthy volunteers (treated with 400 mg/day, twice the maximum recommended daily dose), the upper bound of the 2-sided 90% CI for the time matched Least Square mean difference of QTcF between sertraline and placebo (11.666 msec) was greater than the predefined threshold of 10 msec at the 4-hour postdose time point. Exposure-response analysis indicated a slightly positive relationship between QTcF and sertraline plasma concentrations [0.036 msec/(ng/mL); p&lt;0.0001].</p><p>Based on the exposure response model, the threshold for clinically significant prolongation of the QTcF (i.e. for predicted 90% CI to exceed 10 msec) is at least 2.6-fold greater than the average Cmax (86 ng/mL) following the highest recommended dose of sertraline (200 mg/day) (see sections 4.4, 4.5, 4.8 and 4.9).</p><p><em>Paediatric OCD</em></p><p>The safety and efficacy of Sertraline (50-200 mg/day) was examined in the treatment of non-depressed children (6-12 years old) and adolescent (13-17 years old) outpatients with obsessive compulsive disorder (OCD). After a one week single blind placebo lead-in, patients were randomly assigned to twelve weeks of flexible dose treatment with either Sertraline or placebo. Children (6-12 years old) were initially started on a 25 mg dose. Patients randomized to Sertraline showed significantly greater improvement than those randomised to placebo on the Children&#39;s Yale-Brown Obsessive Compulsive Scale CY-BOCS (p =0.005) the NIMH Global Obsessive Compulsive Scale (p=0.019), and the CGI Improvement (p =0.002) scales. In addition, a trend toward greater improvement in the Sertraline group than the placebo group was also observed on the CGI Severity scale (p=0.089). For CY-BOCs the mean baseline and change from baseline scores for the placebo group was 22.25 &plusmn; 6.15 and -3.4 &plusmn; 0.82, respectively, while for the Sertraline group, the mean baseline and change from baseline scores were 23.36 &plusmn; 4.56 and -6.8 &plusmn; 0.87, respectively. In a post-hoc analysis, responders, defined as patients with a 25% or greater decrease in the CY-BOCs (the primary efficacy measure) from baseline to endpoint, were 53% of Sertraline-treated patients compared to 37% of placebo-treated patients (p=0.03).</p><p>Long term safety and efficacy data are lacking for this paediatric population.</p><p><u>Paediatric population </u></p><p>No data is available for children under 6 years of age</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Absorption</em></p><p>In man, following an oral once-daily dosage of 50 to 200 mg for 14 days, peak plasma concentrations of sertraline occur at 4.5 to 8.4 hours after the daily administration of the drug. Food does not significantly change the bioavailability of sertraline tablets.</p><p><em>Distribution</em></p><p>Approximately 98% of the circulating drug is bound to plasma proteins.</p><p><em>Biotransformation</em></p><p>Sertraline undergoes extensive first-pass hepatic metabolism.</p><p>Based on clinical and in-vitro data, it can be concluded that Sertraline is metabolized by multiple pathways including CYP3A4, CYP2C19 (see section 4.5) and CYP2B6. Sertraline and its major metabolite desmethylSertraline are also substrate of P-glycoprotein in-vitro.</p><p><em>Elimination</em></p><p>The mean half-life of Sertraline is approximately 26 hours (range 22-36 hours). Consistent with the terminal elimination half-life, there is an approximately two-fold accumulation up to steady state concentrations, which are achieved after one week of once-daily dosing. The half-life of N-desmethylSertraline is in the range of 62 to 104 hours. Sertraline and N-desmethylSertraline are both extensively metabolized in man and the resultant metabolites excreted in faeces and urine in equal amounts. Only a small amount (&lt;0.2%) of unchanged Sertraline is excreted in the urine.</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sertraline exhibits dose proportional pharmacokinetics in the range of 50 to</p><p>200 mg.</p><p><u>Pharmacokinetics in specific patient groups</u></p><p><em>Paediatric patients with OCD</em></p><p>Pharmacokinetics of Sertraline was studied in 29 paediatric patients aged 6-12 years old, and 32 adolescent patients aged 13-17 years old. Patients were gradual uptitrated to a 200 mg daily dose within 32 days, either with 25 mg starting dose and increment steps, or with 50 mg starting dose or increments. The 25 mg regimen and the 50 mg regimen were equally tolerated. In steady state for the 200 mg dose, the Sertraline plasma levels in the 6-12-year-old group were approximately 35% higher compared to the 13-17 year old group, and 21% higher compared to adult reference group. There were no significant differences between boys and girls regarding clearance. A low starting dose and titration steps of 25 mg are therefore recommended for children, especially with low bodyweight. Adolescents could be dosed like adults.</p><p><em>Adolescents and elderly</em></p><p>The pharmacokinetic profile in adolescents or elderly is not significantly different from that in adults between 18 and 65 years.</p><p><em>Hepatic impairment</em></p><p>In patients with liver damage, the half life of Sertraline is prolonged and AUC is increased three fold (see sections 4.2 and 4.4).</p><p><em>Renal impairment</em></p><p>In patients with moderate-severe renal impairment, there was no significant accumulation of Sertraline.</p><p><em>Pharmacogenomics</em></p><p>Plasma levels of Sertraline were about 50% higher in poor metabolizers of CYP2C19 versus extensive metabolizers. The clinical meaning is not clear, and patients need to be titrated based on clinical response.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data does not indicate any special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenesis. Reproduction toxicity studies in animals showed no evidence of teratogenicity or adverse effects on male fertility. Observed foetotoxicity was probably related to maternal toxicity. Postnatal pup survival and body weight were decreased only during the first days after birth. Evidence was found that the early postnatal mortality was due to in-utero exposure after day 15 of pregnancy. Postnatal developmental delays found in pups from treated dams were probably due to effects on the dams and therefore not relevant for human risk.</p><p><strong>Juvenile animal studies</strong></p><p>Animal data from rodents and non-rodents does not reveal effects on fertility.&nbsp;</p><p>A juvenile toxicology study in rats has been conducted in which sertraline was administered orally to male and female rats on Postnatal Days 21 through 56 (at doses of 10, 40, or 80 mg/kg/day) with a nondosing recovery phase up to Postnatal Day 196. Delays in sexual maturation occurred in males and females at different dose levels (males at 80 mg/kg and females at &ge;10 mg/kg), but despite this finding there were no sertraline-related effects on any of the male or female reproductive endpoints that were assessed. In addition, on Postnatal Days 21 to 56, dehydration, chromorhinorrhea, and reduced average body weight gain was also observed. All of the aforementioned effects attributed to the administration of sertraline were reversed at some point during the nondosing recovery phase of the study. The clinical relevance of these effects observed in rats administered sertraline has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>q&nbsp; Microcrystalline Cellulose 50 micrometer</p><p>q&nbsp; Anhydrous Calcium Hydrogen Phosphate</p><p>q&nbsp; Sodium Starch Glycolate (Type A)</p><p>q&nbsp; Hydroxypropyl Cellulose (Klucel EF)</p><p>q&nbsp; Magnesium Stearate</p><p>q&nbsp; Hydroxypropyl Methylcellulose Type 2910 (Methocel E5) &nbsp;</p><p>q&nbsp; Polyethylene Glycol 400</p><p>q&nbsp; Titanium Dioxide</p><p>q&nbsp; White Beeswax</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>SETRAL 100 Tablets should not be stored at a temperature above 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&sect;&nbsp; SETRAL 100 Tablets are packed in boxes of 10 Tablets blistered in PVC/ aluminium foil.</p><p>&sect;&nbsp; SETRAL 100 Tablets are packed in boxes of 1000 Tablets blistered in PVC/ aluminium foil.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Jordanian Pharmaceutical Manufacturing Co. Ltd.
PO Box 151
Um Al-Amad 16197
Jordan

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2021.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>